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Summary
Following a request from the European Food Safety Authority (EFSA) to the Panel on Genetically
Modiﬁed Organisms (GMO Panel), a Working Group was established to develop supplementary
guidance for the allergenicity assessment of genetically modiﬁed (GM) plants.
This EFSA GMO Panel document provides supplementary guidance for the risk assessment of GM
plants and derived food and feed, submitted within the framework of Regulation (EC) No 1829/2003.
It supplements the EFSA GMO Panel guidance document on risk assessment of food and feed from GM
plants published in 2011 and Implementing Regulation EU (No) 503/2013. The purpose of this
document is to provide detailed guidance to assist the applicant in the preparation and presentation of
an application according to such Regulation.
In particular, this document addresses three main topics: (i) non-IgE-mediated adverse immune
reactions to food; (ii) in vitro protein digestibility tests; and (iii) endogenous allergenicity.
New scientiﬁc and regulatory developments on these three topics are described. Considerations
regarding the practical implementation of those developments in the risk assessment of GM plants are
discussed and, where appropriate recommendations made to supplement previous guidance
documents.
Brieﬂy, for non-IgE-mediated adverse immune reactions to food detailed risk assessment
considerations are provided to determine the safety proﬁle of the protein or peptide under assessment
with regard to its potential to cause celiac disease. This assessment will include available information
on the source of the transgene and on the protein itself as well as on data from in silico and in vitro
testing, as and when appropriate.
For in vitro protein digestibility tests, the EFSA GMO Panel considers that additional investigations
are needed before any additional recommendation in the form of guidance for applicants can be
provided. To this end, an interim phase is considered necessary to evaluate the revisions to the in vitro
gastrointestinal digestion test, proposed by EFSA, which are presented in an Annex to this document.
For assessing endogenous allergenicity of GM plants and to support the practical implementation of
mandatory requirements in Implementing Regulation EU (No) 503/2013, this guidance document
provides further information on: (i) relevant crops subjected to such analysis; (ii) relevant allergens
that should be quantiﬁed; (iii) methodology to be used for quantiﬁcation; and (iv) principles to be
followed for data interpretation and risk assessment considerations.
During the development of this document, EFSA involved stakeholders and the general public at
different stages, strengthening new means of engagement in its scientiﬁc process.
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1. Introduction
1.1. Background as provided by EFSA
Allergenicity assessment of genetically modiﬁed (GM) plants is performed following the
recommendations laid down in the EFSA Guidance Document (2011). These recommendations are
mainly based on considerations from the EFSA GMO Panel (2010) Scientiﬁc Opinion on allergenicity
assessment of GM plants and microorganisms, and derived food and feed.
In 2012, the European Food Safety Authority (EFSA) launched a procurement call entitled:
‘Literature reviews on: (i) non-IgE-mediated adverse immune reactions to foods, and (ii) in vitro
digestibility tests for allergenicity assessment’. The aim of the project was to obtain relevant
information related to these two topics to be used as background information for further discussion
within the EFSA Panel on Genetically Modiﬁed Organisms (GMO Panel). The review on non-IgE-
mediated adverse immune reactions to food identiﬁed relevant methodology (i.e. in silico and in vitro)
that could be applied in the allergenicity assessment process (Mills et al., 2013a). The review dealing
with in vitro digestibility testing for allergenicity assessment highlighted the need for better
standardisation and harmonisation of the conditions used (e.g. pHs, enzyme:substrate ratios, controls)
when performing in vitro digestibility studies (Mills et al., 2013b).
In addition, the new Implementing Regulation (EU) No 503/20131 (IR503/2013) on applications for
authorisation of GM food and feed has been in place since December 2013. This most recent
regulation includes certain allergens (as deﬁned in OECD Consensus documents) in the compositional
analysis, and consequently, the requirement for quantitative measurement of individual allergens. The
development of supplementary guidelines on this topic would be useful to assist both applicants and
risk assessors in the practical implementation of this requirement.
Therefore, the EFSA GMO Panel was of the opinion that supplementary guidelines on allergenicity
assessment are needed to incorporate new developments in the area into the risk assessment process.
1.2. Terms of Reference as provided by EFSA
The tasks of the Working Group of the GMO Panel are (i) to develop supplementary guidelines for
the allergenicity assessment of GM plants; (ii) to participate in a workshop with stakeholders organised
by EFSA; (iii) to consult the public on the draft Scientiﬁc Opinion; and (iv) to review and revise the
draft Scientiﬁc Opinion accordingly.
1.3. Objectives
This guidance document is designed to assist applicants in the preparation and presentation of a
well-structured application to demonstrate the safety of the GM plant under assessment, with respect
to the allergenicity risks. Recommendations are also provided for the correct interpretation of the data
in the risk assessment process.
EFSA will continue to review the state-of-the-art in science and in the light of experience gained
from the evaluation of GM plant applications, updating the guidance document, as and when
appropriate.
1.4. Scope
This document provides supplementary guidance for the risk assessment of GM plants and derived
food and feed, submitted within the framework of Regulation (EC) No 1829/20032. It supplements the
Guidance Document on risk assessment of food and feed from GM plants (EFSA GMO Panel, 2011) and
IR503/2013.
The supplementary Guidance Document addresses three main topics: (i) non-IgE-mediated adverse
immune reactions to food; (ii) in vitro protein digestibility tests; and (iii) endogenous allergenicity.
1 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. Ofﬁcial Journal of the European Union L157, p.
1–48.
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, 1–23.
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The purpose of this document is to provide detailed guidance to assist the applicant in the preparation
and presentation of an application, according to Articles 5(8) and 17(8) of Regulation (EC) No 1829/
2003. Speciﬁc guidance on the submission of an application will be revised by EFSA, accordingly.
1.5. Transition period
The transition period to allow for the implementation of the EFSA recommendations – the precise
time point from the time of adoption of this document when the requirements laid down in this
guidance document will be fully applicable to newly submitted applications – is as follows.
For non-IgE-mediated adverse immune reactions to food, a 6-month transition period is considered
appropriate. While a period of 3 months would have been in line with the indicative timelines for the
applicant to submit updated bioinformatic analysis (EFSA, 2014), an overall 6-month period is
considered adequate because a new algorithm, even if simple, will be needed.
For endogenous allergenicity, if plant material needs to be generated for testing, a 24-month
transition period is considered appropriate (in line with indicative timelines for the applicant to submit
similar requests, EFSA 2014). If plant material does not need to be generated, a 12-month period is
considered appropriate for the applicants to fully align the strategy for the selection and measurement
of relevant allergens as recommended in this EFSA guidance document. It is noted that assessment of
endogenous allergenicity is currently required in IR503/2013 and that the present document provides
additional considerations regarding the practical implementation of such a requirement. Based on the
experience gained reviewing applications submitted under IR503/2013, many relevant allergens have
already been selected and measured by applicants.
For the remaining topic on in vitro protein digestibility testing, the EFSA GMO Panel considers that
additional investigation is needed before any further recommendation in the form of guidance for
applicants can be provided. To this end, an interim phase is considered necessary to evaluate the
revisions proposed by EFSA to the in vitro gastrointestinal digestion test, which is presented in
Annex B. During this interim phase, the laboratory(ies) involved will further detail and apply the reﬁned
digestion test methodology proposed by the EFSA GMO Panel. After this period, EFSA will evaluate
whether the test adds value and, if so, what further steps are needed for its ﬁnal implementation in
the form of guidance for applicants, which will focus only on in vitro protein digestibility testing. During
such interim phase and until the evaluation of the new approach is completed, the EFSA GMO
Panel will continue to follow the weight-of-evidence approach for allergenicity assessment as described
by the EFSA (EFSA GMO Panel, 2011) and Codex Alimentarius (Codex Alimentarius, 2003, 2009).
2. Allergenicity assessment
Food allergies represent an important public health problem affecting approximately 2–4% of the
adult population and up to 8–9% of children (medically diagnosed), the prevalence rate for self-
reported food allergy being several times higher (EFSA NDA Panel, 2014). Essentially, the only way to
avoid triggering reactions in individuals who are already allergic is avoidance of the relevant food(s).
Nevertheless, it has been previously noted that in everyday life strict avoidance of speciﬁc foods is
difﬁcult to achieve (Crevel et al., 2008) and not completely effective in preventing allergic reactions
(Madsen et al., 2010; Fernandez et al., 2013).
Concerning the potential allergenicity of (novel) proteins, there is in practice no possibility to ensure
full certainty, as to the absence of allergenic risk. There is no single test or parameter that, on its own,
can provide sufﬁcient evidence to predict the allergenicity of a protein or peptide. This is because our
understanding of what causes a protein or a peptide to become allergenic in susceptible individuals is
incomplete. Furthermore, the development of allergic disease depends not only on the allergen but
also on genetic predisposition of the individual and other environmental factors. Nevertheless, a high
degree of conﬁdence in genetically modiﬁed organisms (GMOs) safety can be reached using a weight-
of-evidence approach (EFSA, 2006; Codex Alimentarius 2009; EFSA GMO Panel, 2011). Importantly,
this approach must be based on the best and most up-to-date scientiﬁc knowledge and
methodologies. The ﬁeld of molecular biology is rapidly developing and consequently regulations and
guidance documents need to be updated, as and when appropriate, to take scientiﬁc advances on
board and to reduce remaining uncertainty after a weight-of-evidence evaluation.
To this end, and following the outcome of an EFSA procurement regarding literature reviews on
(i) non-IgE-mediated adverse immune reactions to food and (ii) in vitro digestibility tests for
allergenicity assessment of the newly expressed protein, the EFSA GMO Panel identiﬁed new scientiﬁc
Guidance on allergenicity assessment of GM plants
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(6):4862
information to be considered in the allergenicity assessment of GMOs. In addition, the more recent
IR503/2013 on applications for authorisation of GM food and feed included the mandatory
measurement of certain allergens in the compositional analysis of GM plants. The development of a
supplementary guidance document on the topic of allergenicity was considered necessary to assist
both applicants as well as risk assessors.
Within this context, in 2014 a Working Group of the EFSA GMO Panel was established to develop
a supplementary guidance document on allergenicity assessment of GMOs focusing on three topics:
(i) non-IgE-mediated adverse immune reactions to food; (ii) in vitro protein digestibility testing; and
(iii) endogenous allergenicity in the recipient plant. A stakeholder meeting to provide early input to the
guidance development was held in Brussels in June 2015.3 To further secure timely feedback to the
EFSA GMO Panel Working Group during the guidance development, a ‘Focus group’ was established.4
Additional engagement with stakeholders took place during a public consultation,5 and a subsequent
EFSA info session to further address comments received.6
2.1. Non-IgE-mediated adverse immune reactions to foods
Non-IgE-mediated adverse immune reactions to antigenic food components comprise a large group
of diseases, mostly occurring during childhood. Of these, the best characterised diseases include food
protein-induced enterocolitis (FPIES), as well as eosinophilic diseases of the gastrointestinal tract,
where food products play a role in the pathogenesis (eosinophilic oesophagitis, proctocolitis) (see
Annex A). However, the exact pathogenic mechanisms of these diseases are insufﬁciently understood,
and the diagnosis mostly relies on positive food challenges. Thus, insights about the food components
involved on the molecular level and knowledge on clearly recognised immune mechanisms for these
diseases are currently lacking.
In contrast, celiac disease (CD) is a well characterised non-IgE-mediated adverse immune reaction
to food, and the food proteins involved were described (Koning et al., 2015; van Bergen et al., 2015;
Annex A). Here, gluten has been identiﬁed as the environmental trigger initiating the immune reaction.
The involvement of the immune system in the disease is well established, as pro-inﬂammatory T cells
speciﬁc for gluten fragments bound to the disease-predisposing HLA-DQ2 or HLA-DQ8 molecules are
typically present in the inﬂamed intestine of patients. This T-cell response also leads to the production
of IgA autoantibodies speciﬁc for tissue transglutaminase. CD diagnosis is based on the examination of
characteristic histopathological changes in small intestinal biopsies in combination with serological tests
with positive IgA against tissue transglutaminase being the most reliable.
Consequently, at the present time, assessment of newly expressed proteins with regard to non-IgE-
mediated adverse immune reactions should focus only on CD. For other non-IgE-mediated adverse
immune reactions to foods than CD, additional knowledge on the pathogenic mechanisms is necessary
before they can be considered into the allergenicity assessment.
2.1.1. Celiac disease
CD is a disease of the small intestine characterised by ﬂattening of the intestinal mucosa, resulting
in a variety of clinical symptoms including malabsorption, failure to thrive, diarrhoea and stomach
ache. A detailed description of the pathogenesis of the disease can be found in Annex A.
Brieﬂy, the disease is caused by an uncontrolled intestinal immune response to gluten proteins in
wheat (Triticum spp), gluten-like hordeins in barley (Hordeum vulgare) and secalins in rye
(Secale cereale) (Green and Cellier, 2007). Oat (Avena sativa) is generally considered safe for patients
(Garsed and Scott, 2007), although exceptions were reported (Lundin et al., 2003; Comino et al.,
2015). The only available treatment is a lifelong gluten-free diet implying the exclusion of all food
products that contain wheat, barley and rye or gluten and gluten-like proteins from these cereals. CD
affects approximately 1% of the world population (Abadie et al., 2011).
3 http://www.efsa.europa.eu/en/supporting/pub/899e
4 http://www.efsa.europa.eu/sites/default/files/assets/shp_dg_guidance_document_allergenicity.pdf
5 http://www.efsa.europa.eu/en/consultations/call/160726
6 http://www.efsa.europa.eu/en/events/event/161123
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2.1.2. Risk assessment considerations
A large number of methods and tests can be used to investigate the potential (detrimental)
properties of proteins and peptides under assessment with regard to CD, but in practice it will not be
necessary to apply this full array to safeguard CD patients.
Rather, an integrated, stepwise, case-by-case approach should be used in the assessment of the
newly expressed protein(s) in relation to its(their) potential to cause CD. This overall strategy is in line
with the general principles followed for the allergenicity assessment of newly expressed protein(s) as
deﬁned by EFSA (EFSA GMO Panel, 2011) and Codex Alimentarius (2009). In this context and brieﬂy,
the ﬁrst step in the assessment should consider the available information on the source of the protein
and on the human exposure to the protein itself. This knowledge on the protein can be used to
calibrate the risk assessment strategy to follow on a case-by-case basis. If the available knowledge on
the protein under assessment is insufﬁcient to support its safety, additional considerations on its
properties are necessary to investigate the potential to cause CD. To this end, in silico approaches can
be employed, starting with searches for sequence identity (e.g. searches with known CD peptide
sequences and motif searches). In a second step, if concerns from the sequence identity search are
present, in silico peptide modelling can be applied. When potentially CD relevant sequences which
cannot be disregarded by in silico testing are identiﬁed, in a third step other in vitro tests such as HLA-
DQ-peptide binding assays and/or testing with T-cell clones derived from patients with CD (Figures 1
and 2) can be performed to determine the safety proﬁle of the protein/peptide under assessment.
Further details on the approach to follow can be found below.
A) Step 1 – knowledge on the protein/searches for sequence identity
Knowledge on the protein
Knowledge on the protein should include detailed information on the source of the transgene as
regard its use as food and solid documented information that the protein itself is consumed by
individuals with CD without causing the disease. An exposure assessment might be necessary to
support this consideration.
If the knowledge on the protein is unavailable or insufﬁcient to support its safety, additional
considerations are needed as described below (see also Figure 1).
Searches for sequence identity
a) Searches involving a perfect sequence match with known CD peptide sequences
It is well established that prolamins and closely related proteins (Shewry et al., 2003) harbour the
sequences that cause CD (Tye-Din et al., 2010). Therefore, an initial consideration is to determine if
the protein of interest belongs to these families of proteins. Thus, identity searches with known CD
peptide sequences (see Annex A-1) should be performed. If this search results in a perfect match with
a peptide sequence known to cause CD, a hazard has been identiﬁed.
If this is not the case and there is insufﬁcient knowledge on the protein under assessment, further
investigations to identify/dismiss proteins/peptides that could potentially cause CD should be provided
(Figures 1 and 2).
b) Searches involving a partial sequence match with known CD peptide sequences
T cells respond to antigenic peptides bound to an HLA-molecule. In the case of CD, it concerns
gluten-derived peptides bound to either HLA-DQ2 or -DQ8. However, it is well known that such T cells
can also respond to peptides in which one or more amino acids are replaced. This is the basis, for
example, for T-cell cross-reactivity towards gluten peptides and homologous, but not identical,
peptides derived from barley and rye. For this reason, antigenicity of a protein or fragments thereof for
patients with CD cannot be excluded only on the basis of a lack of a perfect match with gluten
sequences.
– Searches for sequence identity with the Q/E-X1-P-X2 motif (Figure 3):
Examination of the list of epitopes currently identiﬁed (see Annex A-1) reveals that a characteristic
Q-X1-P-X2 motif is present in the large majority of HLA-DQ2 epitopes. This motif is a target for the
enzyme tissue transglutaminase 2 (TG2) which yields E-X1-P-X2 (X1 = L, Q, F, S or E; X2 = Y, F, A, V or
Q; for further details see Figure 3 and Annex A).
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Additional considerations on the position and nature of adjacent amino acid sequences to the
Q/E-X1-P-x2 motif should also be taken into account when performing the assessment (examples
are provided in Annex A-2). If concerns are raised, additional tests will be required (Figures 1 and 2).
– Searches for sequence identity without the Q/E-x1-P-x2 motif:
Few known CD peptide sequences do not contain the Q/E-X1-P-X2 motif. Therefore, an identity
search with known CD peptide sequences, which do not contain a Q/E-X1-P-X2 motif, should be
performed allowing one or more amino acid mismatches. The position and nature of the mismatched
and identical amino acids determine if the peptide sequence has the potential to be a T-cell stimulatory
epitope (additional considerations and examples are provided in Annex A-2). If concerns are raised,
additional tests will be required (Figures 1 and 2). Known CD peptide sequences are listed in Table A.1
as well as in publicly available celiac peptide databases (see Annex A-1).
Following these searches for sequence identity, four outcomes are possible:
• if the Q/E-X1-P-X2 motif is not present and no concerns are raised during the identity search
with speciﬁc known CD peptide sequences, the probability of a T-cell epitope is unlikely;
• if the Q/E-X1-P-X2 motif is not present but concerns are raised during the identity search with
speciﬁc known CD peptide sequences, further investigation is required;
• if the Q/E-X1-P-X2 motif is present and considerations on adjacent sequences can be used to
eliminate concerns, the probability of a T-cell epitope is unlikely;
• if the Q/E-X1-P-X2 motif is present and considerations on adjacent sequences cannot be used
to eliminate concerns, a potential T-cell epitope is detected and further investigation is
required.
Further details on the search for sequence identity are listed in Annex A-2.
B) Step 2 – HLA-DQ-peptide modelling
Several HLA-DQ2-gliadin and HLA-DQ8-gliadin structures are publicly available. These structures can
be used to model a peptide of interest into HLA-DQ2 or HLA-DQ8. This HLA-DQ-peptide modelling can
then allow for a comparison, which can indicate the likelihood that such a peptide will bind to HLA-DQ2
or HLA-DQ8 and will provide insights into the position and orientation of the T-cell receptor contact
residues in the HLA-DQ-bound peptide.
Two outcomes are possible:
• if no relevant HLA-DQ binding and/or similarity with the available HLA-DQ-gliadin structures are
predicted, the probability of a T-cell epitope is unlikely;
• if HLA-DQ binding and a high degree of similarity with the available HLA-DQ-gliadin structures
are predicted, this indicates potential cross-reactivity of the investigated peptide. Consequently,
the potential capacity of the peptide to trigger CD should be determined by additional in vitro
approach(es) described below.
Further details on this step are listed in Annex A-3.
C) Step 3 – In vitro approaches
Proposals of in vitro approaches that can be used to further investigate the potential of the newly
expressed protein to cause CD are found below.
HLA-DQ peptide binding assays:
For peptides to evoke T-cell responses, they must bind to HLA-molecules. HLA-DQ2- and HLA-DQ8-
speciﬁc peptide binding assays were developed and can be exploited to determine the likelihood that
peptides under investigation might be immunogenic.
Two outcomes are possible:
• if high afﬁnity binding is detected (see Annex A-4), further testing is required;
• if low or no afﬁnity binding is detected, the probability that the peptide is immunogenic is low.
Therefore, no further testing is required.
For further details, please see Annex A-4 for an overview of publications that have reported
HLA-DQ-peptide binding assays.
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T-cell testing:
Recognition of gluten peptides by CD4+ T cells from one or more CD patients has been a
prerequisite for deﬁning toxic CD peptides (Sollid et al., 2012).
Such T cells were isolated in a number of laboratories where the necessary expertise and
appropriate infrastructure are available. These T cells were used to provide conclusive evidence on the
capacity of a speciﬁc peptide sequence to stimulate CD-causative T-cell responses. If a T-cell response
with the protein/peptide under assessment is observed, then a hazard has been identiﬁed.
For further details, please see Annex A-5 for an overview of publications that have reported T cells
speciﬁc for HLA-DQ-gluten complexes.
In vitro protein digestibility:
Due to the proline-rich nature, gluten proteins are highly resistant to proteolytic degradation. This
results in relatively long peptides that harbour one or more T-cell stimulatory epitopes. Further details
are listed in Annex A-6 and in the chapter on in vitro protein digestibility testing (Annex B).
Search for sequence 
identy
T-cell tesng
In vitro 
digesbility*
HLA-DQ 
binding assays
modelling
Step 1
Stepwise approach for risk assessment
Knowledge on the 
protein (exposure, 
source, etc.)
* For details, please see chapter on in vitro digesbility.
If concerns 
are raised
If concerns 
are raised Step 2 Step 3
If 
insuﬃcient
Figure 1: Stepwise approach for risk assessment
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2.2. In vitro protein digestibility tests
2.2.1. Risk assessment considerations
In vitro digestibility tests can provide useful data on the susceptibility of a protein to digestion
which can reﬂect its digestibility in the human gastrointestinal tract and subsequently provide
Figure 2: Search for sequence identity
Figure 3: Q/E-X1-P-X2 motif: possible combinations for the Q/E-X1-P-X2 motif found in the large
majority of identiﬁed immunogenic gluten-derived epitopes. It was noted that, while
position 1 is always either glutamic acid (E) or glutamine (Q) and position 3 always consists
of a proline (P), also positions 2 (X1) and 4 (X2) are restricted to certain amino acids
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information on its immunogenicity. There is evidence that gastrointestinal digestion can affect the
immunogenicity of dietary proteins related to both IgE and non-IgE-mediated adverse reactions to
foods (see Annex B). Therefore, in vitro protein digestion can be used as an additional piece of
information in the weight-of-evidence approach followed for the allergenicity assessment of newly
expressed proteins, because no single test is fully predictive of the allergenic potential of a protein
(Codex Alimentarius, 2003, 2009; EFSA GMO Panel, 2011).
The pepsin resistance test is the most commonly used digestion test for this assessment, in line
with international guidelines (Codex Alimentarius 2003, 2009), the EFSA Guidance Document (2011)
and Implementing Regulation (EU) No 503/2013 (IR503/2013). EFSA previously highlighted the
limitations of the classical pepsin resistance test for allergenicity risk assessment and recommended
that resistance to digestion of (novel) proteins should be evaluated using other in vitro digestibility
methods designed to more closely simulate the conditions of the human digestion process (EFSA GMO
Panel, 2010, 2011).
In Annex B of the present document and based on state-of-the-art in science, the EFSA GMO
Panel proposes a reﬁned in vitro digestion test that extends the conditions currently used in the
classical pepsin resistance test in order to better reﬂect the range of conditions found in vivo. This
elaborated test includes additional conditions more representative of the gastric environment with
regard to pH and pepsin levels, together with an intestinal digestion phase. In addition, more
informative read-outs of the test are laid out which deﬁne the extent to which either the intact protein
or resistant fragments remain after in vitro digestion.
The EFSA GMO Panel considers that additional investigation is needed before any additional
recommendation in the form of guidance for applicants can be provided on the proposed in vitro
protein digestibility tests.
To this end, an interim phase (~ 2 years duration) is considered necessary to evaluate the proposed
revisions to the in vitro gastrointestinal digestion test (see Annex B). During this interim phase, the
laboratory(ies) involved, working with EFSA, will further detail and apply the reﬁned digestion test
methodology. After this period, EFSA will assess whether the test adds value to the allergenicity risk
assessment and, if so, what further steps are needed for its ﬁnal implementation in the form of
guidance for applicants. An outline proposal for such an interim phase is provided in Annex B-5.
During the interim phase, and until the evaluation of the new approach is completed, the EFSA
GMO Panel will continue to follow the weight-of-evidence approach for allergenicity assessment as
described by EFSA (EFSA GMO Panel, 2011) and Codex Alimentarius (Codex Alimentarius, 2003, 2009).
2.3. Endogenous allergenicity
According to the EFSA Guidance Document (EFSA GMO Panel, 2011) and in line with principles of
Codex Alimentarius (2003, 2009), endogenous allergenicity assessment of GM plants is a relevant
element to be considered. The purpose of the assessment of endogenous allergenicity is to investigate
that no unintended effect of the genetic modiﬁcation changes the levels of endogenous allergens in a
manner that would adversely impact on human and animal health (EFSA GMO Panel, 2011; K€onig et al.,
2004; Metcalfe et al., 1996; Thomas et al., 2008). This follows the same principles as those used to
support the measurement of any other compound/endpoint in the compositional analysis of GM plants.
EFSA (EFSA GMO Panel, 2011) and Codex Alimentarius (2003, 2009) foresee the assessment of
endogenous allergenicity only when the plant receiving the new gene(s) is recognised to be allergenic.
In these cases, any potential change in the overall allergenicity of the GM plant compared with that of
its non-GM comparator(s) should be analysed. Historically, this analysis was performed using sera from
allergic individuals, but limitations of this assay for routine risk assessment purposes have been
previously described (Fernandez et al., 2013; Selb et al., 2017).
EFSA has previously recommended the inclusion of relevant endogenous allergens in the
comparative compositional analysis, implying the quantitative measurement of individual allergens
(EFSA GMO Panel, 2010, 2011). This recommendation became a mandatory requirement when
Implementing Regulation (EU) No 503/2013 (IR503/2013) on applications for authorisation of GM food
and feed came into force. To assist applicants and risk assessors in its practical implementation, this
supplementary guidance document provides further information on: (i) relevant crops for analysis; (ii)
relevant allergens for quantiﬁcation; (iii) methodology for quantiﬁcation; and (iv) principles to be
followed for data interpretation and risk assessment considerations.
The EFSA GMO Panel Guidance Documents are continuously updated to consider new scientiﬁc and
regulatory developments in the ﬁeld. To this end, further revisions and updates to this supplementary
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EFSA Guidance Document might be needed once experience has been gained with the assessment of
endogenous allergenicity and the new strategies/tools being deployed to support them.
2.3.1. Relevant crops for analysis
According to IR503/2013 and in line with EFSA Guidance Document (EFSA GMO Panel, 2011), an
assessment of endogenous allergenicity should be performed on a case-by-case basis. When the
recipient plant is recognised to be allergenic, the applicant should test any potential change in the
allergenicity of the GM food or feed by comparison of the allergen repertoire with that of its
appropriate comparator(s).
To date, EFSA has performed endogenous allergenicity risk assessments based on experimental
data for foods recognised to be common food allergens and of public health importance as listed in
Annex II of the European Regulation on food information to consumers.7,8 In this context, soybean is
recognised to be a common allergenic food and EFSA GMO Panel Scientiﬁc Opinions on GM soybean
applications, which included an endogenous allergenicity assessment, were published previously
(Annex C-1). To date, EFSA has not received any application involving a common allergenic food other
than soybean. For crops not recognised as being commonly allergenic, speciﬁc experimental data on
endogenous allergenicity are not requested by EFSA. In these cases, the assessment is carried out
considering potential effects of the genetic modiﬁcation on the general composition and molecular
characteristics of the GM plant. However, this does not preclude EFSA requesting experimental data on
endogenous allergenicity for these, if considered necessary, e.g. if the allergenic status of these foods
changes. In addition, other plant-derived foods not currently listed in Annex II of such European
Regulation (e.g. fruits), which might be genetically engineered in the future, should be subjected to
such assessments if considered necessary. For such considerations, risk assessors, risk managers,
health professionals and stakeholders can provide valuable input.
2.3.2. Relevant allergens for quantiﬁcation
Soybean
Soybean is recognised as a common allergenic food by European Regulation,7,8 and suggested as
one of the eight foods accounting for approximately 90% of food allergies (FDA, 2004; OECD, 2012).
The quantitative measurement of soybean allergens as part of the compositional analysis is now a
mandatory requirement in the IR503/2013 where reference to allergens in OECD consensus document
is provided.
In the OECD consensus document on soybean, proteins termed as ‘potential allergens’ are
described in Table 20, Section III-C (OECD, 2012). Nevertheless, in accordance with Article 5(2) and 5
(3) of the IR503/2013: (i) EFSA may accept derogations from speciﬁc requirements, if they are
demonstrated not to be scientiﬁcally necessary for food/feed safety assessment or technically not
possible to perform; and/or (ii) EFSA may request data not foreseen in OECD consensus documents
anytime, if considered necessary based on new scientiﬁc ﬁndings.
In line with IR503/2013, the OECD allergen list should be taken as the starting point for the
collection of ‘potential allergens’ (Figure 4). In addition, this list should be complemented with
searches in the scientiﬁc and medical literature, and in various updated databases (EFSA GMO Panel,
2010; Appendix 3.13, Table I for a list of relevant databases). It is noted that on the one hand the
OECD list of allergens might not be complete at a given point in time, e.g. it might be out dated and/or
miss relevant (more recent) entries. On the other hand, not all ‘potential allergens’ listed in this OECD
consensus document can currently be measured due to technical reasons (e.g. amino acid sequence
not available) and/or their clinical relevance might not have been demonstrated. Once a
comprehensive search of ‘potential allergens’ in the literature and databases is conducted, the relevant
allergens selected for quantiﬁcation and subsequent comparative analysis should be justiﬁed. As a
complementary and/or alternative approach, a systematic review could be performed, aiming to
7 EC, 2003. Directive 2003/89/EC of the European Parliament and of the Council of 10 November 2003 amending Directive
2000/13/EC as regards indication of the ingredients present in foodstuffs.
8 EC, 2011. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision
of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European
Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission
Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC
and 2008/5/EC and Commission Regulation (EC) No 608/2004.
Guidance on allergenicity assessment of GM plants
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2017;15(6):4862
identify clinically relevant allergens. A scientiﬁc rational, explaining why an allergen is not considered
relevant should be provided. A representation of these considerations can be found in Figure 4.
A possible approach how to identify proteins relevant for the endogenous allergenicity assessment
of soybean is described in Annex C-2.
Other GM plants
For foods other than soybean which are recognised allergenic (risk assessors, risk managers, health
professionals and stakeholders can provide valuable input), a similar approach/strategy for the
identiﬁcation of relevant allergens as the one followed for soybean (see Annex C-2) should be applied,
whenever considered necessary. To date, EFSA has not received any application involving a common
allergenic food other than soybean.
2.3.3. Methodology for quantiﬁcation
Either enzyme-linked immunosorbent assay (ELISA) or mass spectrometry (MS) approaches are
appropriate methods for the quantiﬁcation of endogenous allergens, both allowing the speciﬁc
detection and quantiﬁcation of single known allergens. Further considerations on these methodologies
are described in Annex C-3.
2.3.4. Data interpretation and risk assessment
According to IR503/2013, conclusions of the allergenicity assessment should indicate ‘whether the
genetically modiﬁed food or feed is likely to be more allergenic than its conventional counterpart’.
The starting point in the assessment is the identiﬁcation of any potential change in the allergenicity of
the GM food or feed by comparison of the allergen repertoire of the GM plant and its conventional
counterpart, taking into account natural variability.
Allergens included in the compositional analysis should be measured and analysed according to the
principles of the comparative assessment performed for any other compositional compounds (see
section 1.3.2 of IR503/2013). To this end, the starting point of the assessment should be the
identiﬁcation of statistically signiﬁcant differences between the GM plant and its conventional
counterpart. A further evaluation should investigate whether or not the differences observed fall within
or outside the range of natural variation estimated from the reference varieties included in the ﬁeld
trial, i.e. the equivalence test (IR503/2013). In case the levels of a speciﬁc allergen in a GM plant
increases signiﬁcantly from the levels observed in the appropriate comparator(s) and falls outside the
estimated range of natural variation, the biological relevance in relation to human and animal health
should be assessed.
Additional considerations and/or experimental data might be needed on a case-by-case basis. As
for other compounds included in the compositional analysis, the nature of these additional
considerations and/or experimental data depend on the number and magnitude of the changes
identiﬁed, as well as on the clinical/safety relevance of the speciﬁc allergen(s)/compound(s) involved.
Ultimately, when a potential increase in allergenicity due to the genetic modiﬁcation cannot be
excluded, the GM food or feed should be further characterised in the light of its anticipated intake, as
requested by IR503/2013. Occupational allergy should also be considered with respect to inhalation or
contact with potential allergens. In all cases, an exposure assessment should focus on the European
population aiming at identifying particular groups at high risk, which might be affected by a speciﬁc
change of the allergen content.
Possible approaches for data interpretation and risk assessment of soybean endogenous
allergenicity are summarised in Annex C-4.
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Documentation provided to EFSA
1) Proposal for a self-task mandate of the EFSA GMO Panel to establish a Working Group to
develop supplementary guidelines for the allergenicity assessment of GM plants to
incorporate new developments. May 2014. Submitted by the Chair of the ESA GMO Panel.
2) Acceptance of the self-task mandate of the EFSA GMO Panel to establish a Working Group
to develop supplementary guidelines for the allergenicity assessment of GM plants to
incorporate new developments. July 2014. Submitted by EFSA Executive Director.
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CD celiac disease
DBPCFC double-blind placebo-controlled food challenge
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FPIES food-protein induced enterocolitis
GANA N-carbobenzoxy-diglycyl-L-arginyl-2-naphthylamide hydrochloride
GGPNA c-glutamyl-p-nitroanilide
GM genetically modiﬁed
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GMO genetically modiﬁed organism
HMW high molecular weight
IgA immunoglobulin A
IgE immunoglobulin E
LMW low molecular weight
MHC major histocompatibility complex
MS mass spectrometry
MS-MS tandem mass spectrometry
OECD Organisation for Economic Co-operation and Development
PPI proton pump inhibitor
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TG2 transglutaminase 2
Guidance on allergenicity assessment of GM plants
www.efsa.europa.eu/efsajournal 17 EFSA Journal 2017;15(6):4862
Annex A – Non-IgE-mediated adverse immune reactions to foods
Background
Celiac disease (CD) has a strong genetic component. It is associated with particular immune
response genes, i.e. those responsible for the class II major histocompatibility complex (MHC)
molecules, called HLA in humans. Most CD patients express particular HLA-DQ-molecules. HLA-DQ
molecules are dimers of an alpha-(DQA1) and a beta-(DQB1) chain. Like all HLA-molecules, HLA-DQ
molecules bind short peptides and present these to T cells of the immune system. While T cells ignore
HLA-bound peptides derived from harmless (‘self’) proteins, HLA-bound peptides derived from
pathogens are speciﬁcally detected and this recognition leads to the generation of a protective T-cell
response and eradication of the pathogen. The large majority of CD patients (approximately 95%)
express HLA-DQ2.5 (DQA1*05:01, DQB1*02:01) (Sollid et al., 2012) while the remainder are usually
HLA-DQ8 positive (DQA1*03, DQB1*03:02). The few patients that express neither DQ2.5 nor DQ8,
often express HLA-DQ molecules that contain only one of the DQ2.5-chains, e.g. DQ2.2 (DQA1*02:01,
DQB1*02:01) or DQ7.5 (DQA1*05, DQB1*03:01) (Karell et al., 2003). In affected people, but not in
healthy individuals, pro-inﬂammatory gluten-speciﬁc CD4+ T cells are present in the lamina propria of
the affected duodenum. Importantly, these CD4+ T cells recognise gluten peptides only when
presented by the disease associated HLA-DQ molecules (Lundin et al., 1993, 1994; Tye-Din et al.,
2010; Vader et al., 2002b; van de Wal et al., 1998b). In essence, in patients with CD the immune
system displays an aberrant response: the harmless gluten proteins in the food are recognised as
hazardous, leading to a pro-inﬂammatory response as long as gluten is consumed. Elimination of
gluten from the diet constitutes an effective treatment because the T-cell stimulatory gluten peptides
are no longer present. Unfortunately, once a gluten-speciﬁc T-cell response has developed, this leads
to immunological memory and every subsequent exposure to gluten will reactivate the gluten-reactive
T cells and consequently lead to inﬂammation. A lifelong gluten-free diet is thus required.
Gluten is the cohesive mass that remains when starch has been removed from wheat dough
(Shewry et al., 1992). Gluten consists of gliadin and glutenin subcomponents. The gliadins are
subdivided into a-, c- and x-gliadins, and dozens of variants of each type are typically present in a
single wheat variety. The glutenins are subdivided into high molecular weight (HMW) and low
molecular weight (LMW) subunits. The most commonly used wheat varieties are bread wheats
(Triticum aestivum), which are hexaploid species, and pasta wheats (Triticum durum), which are
tetraploid species. Thus, in any single wheat variety up to a hundred different gluten proteins are
listed, many of which are highly similar and only differ by a few amino acids from each other.
T-cell epitopes derived from the a-, c- and x-gliadins as well as from the HMW- and LMW-glutenins
were reported (Arentz-Hansen et al., 2000; Shan et al., 2002; Sj€ostr€om et al., 1998; Vader et al.,
2002b; van de Wal et al., 1998b, 1999). In addition, T-cell epitopes in both hordeins and secalins were
identiﬁed that are highly homologous or identical to those found in wheat (Tye-Din et al., 2010; Vader
et al., 2003). The gluten-like avenins of oat are more distinct; however, avenin-speciﬁc as well as
cross-reactive T-cell responses were described (Arentz-Hansen et al., 2004; Vader et al., 2003).
High afﬁnity binding of peptides to either HLA-DQ2.5 or -DQ8 depends on the presence of one or
more negatively charged amino acids. As gluten proteins are virtually devoid of negatively charged
amino acids, native gluten-derived peptides bind poorly to these HLA-DQ molecules. Due to the activity
of the enzyme tissue transglutaminase 2 (TG2) in the gastrointestinal tract, the required negative
charge(s) are introduced when this enzyme converts glutamine residues within gluten peptides into
negatively charged glutamic acid (Molberg et al., 1998; Vader et al., 2002a; van de Wal et al., 1998a).
These deamidated gluten peptides then bind with increased afﬁnity to HLA-DQ2.5 or -DQ8, and this
stronger binding enhances or causes immunogenicity (van de Wal et al., 1998; Arentz-Hansen et al.,
2000; Henderson et al., 2007; Kim et al., 2004; Moustakas et al., 2000; Quarsten et al., 1999).
The speciﬁcity of TG2 for particular target sequences in gluten proteins plays a crucial role in the
generation of a relatively large number of gluten-derived peptides that bind to HLA-DQ2.5. Glutamine
and proline are abundantly present in gluten proteins, together they comprise over 50% of the amino
acids in gluten. Therefore, Q-X-P and Q-P sequences (where Q is glutamine; P is proline; X is any
amino acid except P) are often found in gluten proteins and TG2 typically deamidates glutamine
residues in Q-X-P sequences, but not in QP sequences (Vader et al., 2002a). Therefore, immunogenic
gluten-derived peptides are typically found in the proline rich-regions of gluten proteins and usually
contain a Q-X-P motif. ‘Classic’ examples of such peptides are the immunodominant T-cell epitopes
present in the N-terminal part of the a-gliadins: PFPQPQLPY and PQPQLPYPQ. In fact, these sequences
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have a 7-amino acid overlap and in both sequences only one Q-residue is a target for TG2, the Q in
the QLPY sequence which allows the introduction of a negative charge at either position 6 or position
4, respectively. In both instances, this generates a gluten peptide that binds with high afﬁnity to HLA-
DQ2.5. The available crystal structures of HLA-DQ2.5-gliadin and the bound cognate T-cell receptor
demonstrate that the negatively charged glutamic acid serves as an anchor residue for peptide binding
to HLA-DQ2.5 and does not contact the T-cell receptor (Petersen et al., 2014). Additionally, the proline-
rich nature of gluten renders these proteins resistant to degradation by enzymes in the gastrointestinal
tract. Relatively long gluten fragments are, therefore, present in the small intestine. This likely
contributes to the immunogenic nature of these peptides (Shan et al., 2002). Thus, at least three
factors contribute to the immunogenicity of gluten: (a) resistance to proteolytic degradation, (b)
speciﬁc recognition by TG2, and (c) peptide binding properties of HLA-DQ2.5 and HLA-DQ8.
The glutamic acid introduced by TG2 is usually in position 4 (p4) or p6 in HLA-DQ2.5 restricted
epitopes and at position p1 and/or p9 in HLA-DQ8 restricted epitopes (Sollid et al., 2012). As a
consequence, HLA-DQ2.5-restricted gluten epitopes carry a proline at either p6 or p8. This positioning
of proline residues is less strict in the case of the DQ8 epitopes. In all cases, the glutamic acid residues
serve as anchors important for binding of the peptides to either HLA-DQ2.5 or -DQ8.
It is important to note that, while polyclonal T-cell responses to multiple T-cell epitopes are usually
detected in CD patients, responses to the DQ2.5-glia-a1, DQ2.5-glia-a2 epitopes and homologues
thereof in the x-gliadins, hordeins and secalins are dominant in DQ2.5-positive patients (Arentz-
Hansen et al., 2000; Tollefsen et al., 2006; Tye-Din et al., 2010). In DQ8-positive patients, responses
to the DQ8-glia-a1 epitope are most frequently found (Tollefsen et al., 2006; van de Wal et al.,
1998b).
The following criteria were used to deﬁne CD reactive epitopes in Sollid et al. (2012):
• reactivity against the epitope must have been deﬁned by at least one speciﬁc T-cell clone;
• the HLA-restriction element involved must have been unequivocally deﬁned;
• the 9-amino acid core of the epitope must have been deﬁned either by an analysis with
truncated peptides and/or HLA-binding with lysine scan of the epitope, or a comparable
approach. In a lysine scan, all amino acids in the sequence of interest are individually replaced
by a lysine and the impact of these single amino acids substitutions on HLA-binding is
determined, information which usually reveals which amino acids in the sequence are required
for binding to HLA.
Because CD is caused by an immune response to a foreign protein and all symptoms disappear
upon withdrawal of gluten from the diet, the condition should not be regarded as a true autoimmune
disease. Autoantibodies speciﬁc for tissue transglutaminase appear to be secondary to the T-cell driven
immune response to gluten and disappear if gluten is eliminated from the diet (Rossjohn and Koning,
2016).
Other conditions linked to wheat or gluten, summarised as ‘non-celiac gluten sensitivity’, are not
part of this document because there are no known deﬁnite underlying pathomechanisms (Aziz et al.,
2015). In the last years, the diagnosis of non-celiac gluten sensitivity has emerged and refers to
clinically diagnosed gluten-related symptoms without criteria for gluten allergy or celiac disease (Czaja-
Bulsa, 2015). The unambiguous diagnosis of this condition is hampered by several facts. Symptoms
are pleomorphic and often vague and limited in time. They mostly concern the gastrointestinal tract,
but can also involve among many others: mood disorders, chronic recurrent headache, chronic fatigue
or muscle disorders. Nevertheless, avoidance of gluten-containing foods leading to symptom relief, and
re-exposure provoking relapse are suggestive of a gluten-related origin of the disease. It can, however,
not be excluded that the symptoms are due to other components present in wheat and related
cereals. The cause of this condition remains undeﬁned. Immune mechanisms have not been identiﬁed
and the character of the symptoms mostly suggests a gluten-intolerance (difﬁcult digestion). Non-
celiac gluten sensitivity seems more prominent in individuals with irritable bowel disease, and in those
suffering of FODMAP intolerance (Biesiekierski et al., 2013).
The current chapter of the guidance document dealing with non-IgE-mediated food sensitivity is at
the current stage of knowledge not addressing non-celiac gluten sensitivity. This disease is currently
only marginally understood, in particular with regard to its mechanism, and is increasingly (mostly self)
diagnosed. Future studies might unravel the exact mechanism of the disease and thus indicate
whether additional risk assessment considerations will be needed – aspects of which we currently have
no evidence/sufﬁcient knowledge.
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To sum up, CD, a condition in which immunological mechanisms were extensively studied, can be
considered as a pathognomonic, gluten-related non-IgE mediated food sensitivity. CD is within the ﬁeld
of this guidance document and has been extensively addressed accordingly.
Annex A-1. T-cell epitopes known in celiac disease
Several listings/databases of the known T-cell stimulatory sequences identiﬁed in gluten, hordeins,
secalins and avenins are available including the https://propepper.net database and the http://www.
allergenonline.org/ database. Furthermore, an overview of the best characterised epitopes along with
a uniﬁed nomenclature is presented in Sollid et al. (2012). Table A.1 lists the epitopes described in the
latter manuscript. This compilation lists both the HLA-DQ2- and HLA-DQ8-restricted epitopes and
includes the known immunodominant epitopes present in the a- and x-gliadins as well as the less
commonly recognised epitopes in the c-gliadins and the LMW- and HMW-glutenins. The list contains a
convenient overview of the most important and well deﬁned epitopes. It is, nevertheless, important to
note that due to the extreme variability of the gluten and gluten-like proteins in barley and rye,
(single) amino acid variants of these epitopes do exist, some of which may also exhibit T-cell
stimulatory activity. Also, it cannot be fully excluded that additional gluten epitopes may be identiﬁed
in the future. However, this is unlikely because large numbers of patients have already been
extensively tested for gluten reactivity, on the basis of gluten peptide libraries (Tye-Din et al., 2010).
Thus, any protein containing one or more sequences that display high sequence identity to the epitope
sequences present in this list will likely have the capacity to trigger gluten-speciﬁc T cells.
The development of a comprehensive database that is publicly available, curated regularly and
appropriately built and designed for risk assessment purposes is an important aspect to be further
investigated.
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Table A.1: List of celiac disease relevant DQ2 and DQ8 restricted T-cell epitopes recognised by
CD4+ T cells (taken from Sollid et al., 2012)
DQ2 restricted epitopes
Epitope Motif Reference
DQ2.5-glia-a1a P F P Q P Q L P Y Arentz-Hansen et al. (2000)
DQ2.5-glia-a1b P Y P Q P Q L P Y Arentz-Hansen et al. (2002)
DQ2.5-glia-a2 P Q P Q L P Y P Q Arentz-Hansen et al. (2000)
DQ2.5-glia-a3 F R P Q Q P Y P Q Vader et al. (2002b)
DQ2.5-glia-c1 P Q Q S F P Q Q Q Sj€ostr€om et al. (1998)
DQ2.5-glia-c2 I Q P Q Q P A Q L Qiao et al. (2005), Vader et al. (2002b)
DQ2.5-glia-c3 Q Q P Q Q P Y P Q Arentz-Hansen et al. (2002)
DQ2.5-glia-c4a S Q P Q Q Q F P Q Arentz-Hansen et al. (2002)
DQ2.5-glia-c4b P Q P Q Q Q F P Q Qiao et al. (2005)
DQ2.5-glia-c4c Q Q P Q Q P F P Q Arentz-Hansen et al. (2002)
DQ2.5-glia-c4d P Q P Q Q P F C Q Qiao (unpublished)
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Annex A-2 Considerations for sequence identity searches
Closer inspection of the Q/E-X1-P-X2 sequences demonstrates that only a limited number of amino
acids are present at the X-positions: L, Q, F, S or E at position X1 and Y, F, A, V or Q at position X2
(Figure 3). Thus, a search motif that incorporates these amino acids should identify peptide sequences
with the potential to bind to HLA-DQ2.5 and stimulate gluten-speciﬁc T cells. Additional considerations
on position and nature of adjacent amino acid sequences to the Q/E-X1-P-X2 motif should also be
taken into account. For example, positively charged amino acids in general diminish the likelihood of
DQ-binding and T-cell recognition, in particular positive charge at positions p1, p4, p6, p7 and p9 are
detrimental. It is noted that P-P is not identiﬁed in T-cell epitopes. In contrast, P-X-P in addition to
Q/E-X1-P-X2 is associated with the most immunogenic epitopes.
As discussed in the document, any 9 amino acid-residue peptide which shows identity to a known
T-cell epitope might be able to induce an immune response in CD patients. However, the necessary
number of amino acids identical in a peptide to trigger a response is challenging to deﬁne, because
the ability to bind to CD-speciﬁc MHC molecules and the interaction with T cells is highly dependent on
the nature and position of certain amino acids. Therefore, a deﬁnite size cut-off in respect to identity
to a known epitope indicating potential hazardous peptides, for which further assessment would be
needed, is demanding. Single amino acids substitutions were described to abolish T-cell reactivity in
epitopes of a-2 gliadin (Ellis et al., 2003, Mitea et al., 2010). On the other hand, a major alpha gliadin
peptide of wheat (glia-a1b, Table A.1) shares ﬁve out of nine amino acids with peptides in oat (DQ2.5-
ave-1(b)), which are highly suspected to induce immune responses in some celiac disease patients
(Vader et al., 2003, Arentz-Hansen et al., 2004). In this case, however, the motif Q/E-X1-P-X2 is
present in both sequences.
Considering the search for sequence identity without the motif, based on current knowledge and
given that the vast majority of sequences that do not contain the motif Q/E-X1-P-X2 are DQ8 epitopes,
it is reasonable to consider allowing three amino acid mismatches. It is highly unlikely that more than
three amino acid mismatches in sequences lacking the motif Q/E-X1-P-X2 would result in a safety
concern. For DQ8 epitopes, the three amino acids mismatch consideration excludes a potential
exchange of glutamines (Q) at position 1 and/or position 9 by glutamic acid (E) where E is known to
DQ2 restricted epitopes
Epitope Motif Reference
DQ2.5-glia-c5 Q Q P F P Q Q P Q Arentz-Hansen et al. (2002)
DQ2.5-glia-x1 P F P Q P Q Q P F Tye-Din et al. (2010)
DQ2.5-glia-x2 P Q P Q Q P F P W Tye-Din et al. (2010)
DQ2.2-glut-L1 P F S Q Q Q Q P V Vader et al. (2002b)
DQ2.5-glut-L2 F S Q Q Q Q S P F Stepniak et al. (2005), Vader et al. (2002b)
DQ2.5-hor-1 P F P Q P Q Q P F Tye-Din et al. (2010), Vader et al. (2003)
DQ2.5-hor-2 P Q P Q Q P F P Q Vader et al. (2003)
DQ2.5-sec-1 P F P Q P Q Q P F Tye-Din et al. (2010), Vader et al. (2003)
DQ2.5-sec-2 P Q P Q Q P F P Q Vader et al. (2003)
DQ2.5-ave-1 P Y P E Q Q E P F Arentz-Hansen et al. (2004), Vader et al. (2003)
DQ2.5-ave-1b P Y P E Q Q Q P F Arentz-Hansen et al. (2004), Vader et al. (2003)
DQ8 restricted epitopes
Epitope Motif Reference
DQ8-glia-a1 Q G S F Q P S Q Q van de Wal et al. (1998b)
DQ8-glia-c1a Q Q P Q Q P F P Q Tollefsen et al. (2006)
DQ8-glia-c1b Q Q P Q Q P Y P Q Tollefsen et al. (2006)
DQ8-glut-H1 Q G Y Y P T S P Q van de Wal et al. (1999)
The single letter code for amino acids is used. A characteristic Q-X1-P-X2 motif is present in the large majority of HLA-DQ2
epitopes (in bold). This sequence is a target sequence for TG2, which yields E-X1-P-X2. Due to the introduction of the negatively
charged amino acid glutamate, the peptides become high afﬁnity binders for HLA-DQ2. glia-a = a-gliadin; glia-c = c-gliadin;
hor = hordein; sec = secalin; ave = avenin; glut-L = LWM-glutenin, glut-H = HMW-glutenin.
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enhance binding to HLA-DQ8. It is noted that these considerations might require adaptations based on
experience gained in the assessment and on additional knowledge acquired.
Few examples illustrating in practical terms such considerations are provided below.
Two immunodominant T-cell epitopes are present in the a-gliadins with partially overlapping
sequences, sequence 1 PFPQPQLPY and sequence 2 PQPQLPYPQ. In these cases, the sequence QLPY
and thus the Q-X1-P-X2 motif is present.
– Example 1, the motif is present.
The protein of interest contains the following sequence ALPLTQLPASR that we called sequence 3.
The comparison of this sequence with sequences 1 (PFPQPQLPY) and 2 (PQPQLPYPQ) is the following.
Comparison of sequences 3 (ALPLTQLPASR) and 1 (PFPQPQLPY):
At position 1 (p1), the P is replaced by A, both being uncharged small amino acids.
At p2, F is replaced by L, both uncharged large amino acids.
At p3, an identical amino acid is present.
At p4, Q is replaced by L, both uncharged large amino acids.
At p5, P is replaced by T, different properties but both small amino acids.
At p6, an identical amino acid is present.
At p7, an identical amino acid is present.
At p8, an identical amino acid is present.
At P9, Y is replaced by A. Here, a large amino acid is replaced by a small amino acid but this
does not prohibit binding to HLA-DQ2 (Petersen et al., 2016).
Overall: there is the potential for cross-reactivity of the 9-amino acid sequence ALPLTQLPA,
additional investigations are needed.
Comparison of sequence 3 (ALPLTQLPASR) but considering ﬁrst P as p1 and sequence 2
(PQPQLPYPQ):
At p1, an identical amino acid is present.
At p2, Q is replaced by L, both uncharged large amino acids.
At p3, P is replaced by T, different properties but both small amino acids.
At p4, an identical amino acid is present.
At p5, an identical amino acid is present.
At p6, an identical amino acid is present.
At P7, Y is replaced by A. Here, a large amino acid is replaced by a small amino acid and at
this position this is known to eliminate T-cell reactivity (Petersen et al., 2016).
At p8, P is replaced by S and this is known to eliminate T-cell reactivity (Mitea et al., 2012).
At p9, Q is replaced by R, a positively charged amino acid and this is known to have a negative
effect of binding to HLA-DQ2.
Overall: there are three signiﬁcant differences, two of which are independently known to
eliminate T-cell reactivity. Altogether, it is highly unlikely that the nine amino acid sequence
PLTQLPASR will bind to HLA-DQ2 and stimulate T cells. No additional investigations for this nine
amino acid sequence are needed.
– Example 2, the motif is present.
The protein of interest contains the following sequence KARGVQSPAEI that we called sequence 4.
The comparison of this sequence with sequences 1 (PFPQPQLPY) and 2 (PQPQLPYPQ) is the following.
Comparison of sequences 4 (KARGVQSPAEI) and 1 (PFPQPQLPY):
At p1, the P is replaced by K, a positively charged amino acid and this is known to have a
negative effect of binding to HLA-DQ2.
At p2, F is replaced by A. Here a large amino acid is replaced by a small amino acid.
At p3, P is replaced by R, a positively charged amino acid.
At p4, Q is replaced by G. Here a large amino acid is replaced by a small amino acid.
At p5, P is replaced by V.
At p6, an identical amino acid is present.
At p7, L is replaced by S. Here, a large amino acid is replaced with a small amino acid that has
different properties.
At p8, an identical amino acid is present.
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At P9, Y is replaced by A. Here, a large amino acid is replaced by a small amino acid but this
does not prohibit binding to HLA-DQ2 (Petersen et al., 2016).
Overall: there are six signiﬁcant differences. Altogether, it is highly unlikely that this sequence
will bind to HLA-DQ2 and stimulate T cells. No additional investigations are needed.
Comparison of sequences 4 (KARGVQSPAEI) but considering R as p1, and sequence 2 (PQPQLPYPQ):
At p1, the P is replaced by R, a positively charged amino acid and this is known to have a
negative effect of binding to HLA-DQ2.
At p2, Q is replaced by G. Here, a large amino acid is replaced by a small amino acid.
At p3, P is replaced by V.
At p4, an identical amino acid is present.
At p5, L is replaced by S. Here, a large amino acid is replaced by a small amino acid that has
different properties.
At p6, an identical amino acid is present.
At P7, Y is replaced by A. Here, a large amino acid is replaced by a small amino acid and at
this position this is known to eliminate T-cell reactivity (Petersen et al., 2016).
At p8, P is replaced by E, a negatively charged amino acid.
At p9, Q is replaced by I, both large non-charged amino acids.
Overall: there are ﬁve signiﬁcant differences, one of which is known to eliminate T-cell
reactivity by its own. Altogether, it is highly unlikely that this sequence will bind to HLA-DQ2
and stimulate T cells. No additional investigations are needed.
– Example 3, the motif is not present.
The protein of interest contains the following sequence: EGSIQAGQQ. This sequence has some
identity to the HLA-DQ8 epitope QGSFQPSQQ where four mismatches (including an exchange of a Q
by an E at position 1) can be identiﬁed.
Comparison of sequence EGSIQAGQQ with sequence QGSFQPSQQ:
At p1, Q has been replaced by E, as previously mentioned; this change is known to enhance
binding to HLA-DQ8.
At p2, an identical amino acid is present. This is an important T-cell receptor contact residue
(Broughton et al., 2012).
At p3, an identical amino acid is present. This is an important T-cell receptor contact residue
(Broughton et al., 2012).
At p4, F is replaced by I, both large uncharged amino acids.
At p5, an identical amino acid is present. This is an important T-cell receptor contact residue
(Broughton et al., 2012).
At p6, P is replaced by A, both small uncharged amino acids.
At p7, S is replaced by G, both small amino acids but with different properties.
At p8, an identical amino acid is present. This is an important T-cell receptor contact residue
(Broughton et al., 2012).
At p9, an identical amino acid is present. This is an HLA-DQ8 anchor residue.
Overall: despite the four amino acid mismatch critical amino acids for HLA-binding and T-cell
recognition are conserved (including a replacement at p1 by E). There is the potential for
cross-reactivity, additional investigations are needed.
Annex A-3. Considerations for HLA-DQ peptide modelling
Recent studies have determined the T-cell receptor repertoire used by CD4+ T cells speciﬁc for
immunodominant gluten epitopes and crystal structures of such T-cell receptors bound to the HLA-DQ-
gluten complexes were determined. As a consequence, detailed knowledge is available indicating
which amino acids in the gluten peptides are responsible for the high-afﬁnity binding to HLA-DQ and
which amino acids mediate the speciﬁc interaction with the T-cell receptor. Several publications
describing the binding of CD peptides to HLA-DQ molecules are available. The coordinates of all these
structures are available through public databases (Broughton et al., 2012; Henderson et al., 2007; Kim
et al., 2004; Petersen et al., 2014; Petersen et al., 2015, 2016; Rossjohn and Koning, 2016). As an
example, the x-ray coordinates of HLA-DQ8 bound to a gliadin peptide were deposited in the Protein
Data Bank (www.rcsb.org) with the accession number 2NNA while the coordinates and structure
factors for the HLA-DQ2-gliadin complexes have been deposited in the Protein Data Bank under the
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following accession codes: S2 TCR–DQ2.5-glia-a1a, 4OZI; S16 TCR–HLA-DQ2a2, 4OZH; D2 TCR–HLA-
DQ2a2, 4OZG; JR5.1 TCR–HLA-DQ2a2, 4OZF. This extensive information allows modelling studies in
which the gluten peptide can be replaced by any peptide sequence of choice (Moustakis et al., 2000;
Wiesner et al., 2008; van Heemst et al., 2015). It can be anticipated that, if the selected peptide is
likely to bind to HLA-DQ in a way that it resembles the known structure of gluten peptides bound to
HLA-DQ, it might have the capacity to stimulate gluten-speciﬁc T cells (Figure A.1, Wiesner et al.,
2008). Thus, molecular modelling can be employed to aid the determination of potential T-cell
stimulatory properties of peptide sequences.
Considering the great relevance of this HLA-DQ peptide modelling step, the future development of
a publicly available software tool speciﬁcally designed for risk assessment purposes is desirable.
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Annex A-4. Considerations for HLA-DQ peptide binding assays
Binding afﬁnities in HLA-DQ-peptide binding assays have been previously reported in the literature
(e.g. Vader et al., 2003). A non-exhaustive list of publications that have reported on HLA-DQ-peptide
binding assays:
Ettinger RA and Kwok WW, 1998. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC
molecule associated with dominant protection in insulin-dependent diabetes mellitus. Journal of Immunology,
160, 2365–2373.
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Johansen BH, Vartdal F, Eriksen JA, Thorsby E and Sollid LM, 1996. Identiﬁcation of a putative motif for binding of
peptides to HLA-DQ2. International Immunology, 8, 177–182.
Figure A.1: Shown is a side view of two peptides, one a gliadin T-cell epitope (top panel) while the
other is a peptide derived from a self-antigen (lower panel). The side chains of the amino
acids that point downwards anchor the peptide to the HLA-DQ-molecule, the upward-
pointing amino acids can be contacted by the T-cell receptor. Even though the peptide
share some sequence similarity (P at p1, L at P7, P at p8, large amino acid at p2), there
are several features that are predicted to prohibit a functional interaction between a
gliadin speciﬁc T-cell receptor and the self-peptide, like an overall different conformation
and the presence of a large amino acids at p5 (Q) instead of the much smaller proline
(P) in the gliadin peptide (taken from Wiesner et al., 2008)
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Chemistry Letters, 8, 2039–2044.
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Annex A-5. Non-exhaustive list of publications that have reported on gluten-speciﬁc T cells
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Annex A-6. Considerations for in vitro digestibility tests
As speciﬁed above and because a 9-amino acid core is almost invariably required for efﬁcient
peptide binding to HLA-DQ, proteins that are easily degraded into fragments shorter than 9 amino
acids are unlikely to harbour T-cell stimulatory epitopes. Thus, determination of proteolytic resistance
of proteins can aid in the identiﬁcation of proteins with potential harmful potential. For more details,
please see chapter on in vitro protein digestibility in this document (Annex B).
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Annex B – In vitro protein digestibility tests
As speciﬁed in Section 2.2 of this document, an interim phase (~2 years duration) is proposed to
assess the utility of an enhanced in vitro digestion test, with a review undertaken in the ﬁnal year.
During this phase, the laboratory(ies) involved will detail and apply the reﬁned digestion test
methodology. After this period, EFSA will discuss whether the test adds value and, if so, what further
steps are needed for its ﬁnal implementation.
Annex B-1. Background
In vitro digestibility tests can provide useful data on the susceptibility of a protein to digestion
which may reﬂect its digestibility in the human gastrointestinal system and subsequent presentation to
the host’s immune system (Foster et al., 2013). There is evidence that gastrointestinal digestion can
affect the immunogenicity of dietary proteins in relation to both IgE and non-IgE-mediated adverse
reactions to foods as discussed below. However, notably, the ability of digestion-resistant dietary
proteins or derived fragments to initiate diseases, such as IgE-mediated allergies or celiac disease
(CD), also depends on the predisposition of the host. For CD, expression of certain HLA genotypes is a
well described risk factor for developing the condition (See Section 2.1). However, while a genetic
predisposition towards atopy is also thought to play a role in the development of IgE-mediated
allergies to a variety of environmental agents including foods, speciﬁc genetic and other risk factors
involved in the development of speciﬁc IgE have yet to be deﬁned. This makes the risk assessment
process less certain for IgE-mediated allergies compared to CD.
IgE-mediated adverse reactions to foods: The events leading to the breakdown of oral tolerance,
allergic sensitisation and development of food allergies in susceptible individuals are poorly
understood. It is likely that multiple pathways could ultimately lead to a failure to develop or loss of
oral tolerance (Chinthrajah et al., 2016). Notwithstanding the role of route of exposure in sensitisation,
understanding how proteins are presented to the gastrointestinal mucosal immune system may
provide insight into the mechanisms controlling the balance between tolerisation and sensitisation.
Furthermore, oral exposure is also central to non-IgE assessments where gastrointestinal digestion has
been demonstrated to be important in delivery of immunologically active fragments to gastrointestinal
mucosal sites. Impaired gastric digestion of food allergens has been associated with both development
of IgE responses to foods (sensitisation) and modulating the severity of IgE-mediated reactions to
foods (elicitation). A recent study of patients undergoing gastric-bypass surgery, a procedure known to
reduce post-prandial gastric acidity and where the bulk of food ingested reaches the small intestine
without prior gastric digestion, resulted in a signiﬁcant increase in sensitisation to food (Shakeri-
Leidenmuhler et al., 2015). Impaired digestion of cod ﬁsh proteins may also be a risk factor for severe
reactions in ﬁsh allergic individuals (Untersmayr et al., 2007). Studies on animal models have shown
that suppression of gastric acid secretion using widely prescribed antacid medication increases
propensity to sensitisation to proteins from cod ﬁsh (Untersmayr et al., 2003), celery (Untersmayr
et al., 2008), hazelnut (Scholl et al., 2005) and egg (Diesner et al., 2008). Furthermore, an association
between the use of antiulcer drugs and the induction of IgE-mediated allergy to a variety of foods
such as milk, potato, celery, carrots, apple, orange, wheat, and rye ﬂour has been reported
(Untersmayr et al., 2005). Such studies suggest that elevated gastric pH, and the resulting reduction in
peptic digestion, may enhance the potential of foods to cause allergies. Uptake of allergens into the
circulation may play an important role in eliciting allergic reactions (Strait et al., 2011) but data in
humans are sparse and conﬂicting as to the role of allergen uptake in triggering reactions, although
uptake appears much greater in allergic than healthy individuals, as indicated in studies of wheat
allergy (Brockow et al., 2015; Matsuo et al., 2005).
Non-IgE-mediated adverse reactions to foods: Studies seeking to deﬁne the structural basis of the
toxicity of gluten in CD have made extensive use of in vitro gastrointestinal digestion, including the
action of brush border proteases, to generate physiologically relevant fragments of gluten. These
studies notably identiﬁed a 33mer peptide that is especially resistant to digestion and which is likely to
persist in the brush border with a half-life estimated to be ~20 h. This peptide is also an excellent
substrate for tissue transglutaminase TG2 and was a potent stimulator of T cells from celiac patients
(Shan et al., 2002).
Such data support the premise that immunologically active fragments of food proteins persisting in
the gastrointestinal lumen can play a role in driving immune-mediated adverse reactions to foods.
Persistent, soluble intact proteins and fragments are more likely to be sampled by the gastrointestinal
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epithelium and are hence exposed to cells of the immune system as potentially immunogenic
fragments, with particulates being sampled by M cells within the Peyer’s patches. In animal models,
there is evidence that uptake of particulate peanut protein bodies by M cells may promote sensitisation
by virtue of their size, with soluble material being taken up by the same route (Chambers et al., 2004).
Although the exact mechanism(s) of antigen uptake in the intestine are still to be clearly elucidated
(Pabst and Mowat, 2012), it is generally accepted that most food allergens should retain sufﬁcient
structural integrity as they pass through the human gastrointestinal tract to sensitise or elicit an
allergic response (Metcalfe et al., 1996). After uptake by antigen presenting cells, peptides generated
through endosomal proteolysis bind to MHC class II molecules (Rudensky et al., 1991; Chicz et al.,
1993). Peptides shorter than 9 amino acid residues are probably unable to bind to MHC class II
molecules and to activate T cells because there is a minimum length requirement – the so called
‘peptide binding register’ (Mohan and Unanue, 2012). Thus, peptides shorter than 9 amino acid
residues are highly unlikely to stimulate an immune response. However, unlike celiac disease, IgE-
mediated allergies involve development of humoral (i.e. antibody) responses which requires activation
of both B cells and T cells. The B-cell receptors involved in B-cell activation have a requirement for
multivalent antigen and it has emerged that the way in which B cells encounter antigen in vivo
depends on its properties, such as size (Harwood et al., 2010). As a consequence, larger peptide sizes
are required for development of IgE responses. Thus, digestion of the allergen b-lactoglobulin into
fragments of less than 3,000 Da abolished the proteins immunogenicity (Bogh et al., 2013), while
peptides of less than 1,500 Da resulting from pepsinolysis of peanut Ara h 1, had markedly reduced
immunogenicity, which was completely lost when the digest was fractionated (Bogh et al., 2012). With
regard to elicitation of reactions, synthetic antigens have been used to investigate the mechanism of
degranulation (Handlogten et al., 2013). These studies have shown that a minimum of two distinct
epitopes is required to trigger degranulation, with the epitopes separated by a maximum of 6.4 nm on
the synthetic antigen. On this basis peptides of at least 3–5 kDa would be required to cross-link IgE
bound to the surface of effector cells, such as mast cells and basophils. However, peptides as small as
791 Da and 1413 Da resulting from the pepsinolysis of the avocado pear allergen Prs s 1, have been
found to inhibit IgE binding to crude avocado extract in ELISA-inhibition assays and to elicit reactions
in vivo using skin testing, respectively (Diaz-Perales et al., 2003). Such peptides are unlikely to carry
multiple IgE epitopes, suggesting that peptide aggregation may play a role in triggering degranulation.
To either sensitise or trigger an allergic reaction in an already sensitised individual, a food protein
needs to be ‘bioaccessible’ by the hosts’ immune system. ‘Bioaccessibility’ describes the ability of a
chemical entity (such as a protein) to be released from food during the digestive process, which can
consequently interact with and/or be absorbed by the gastrointestinal epithelium (Holst and
Williamson, 2008). The EFSA Guidance Document for risk assessment of food and feed from
genetically modiﬁed plants published in 2011 states that ‘the impact of the possible interaction
between the protein and other components of the matrix as well as the effects of the processing
should be taken into account in in vitro digestibility tests’ (EFSA GMO Panel, 2011). In vitro digestibility
tests have been applied to investigate the effects of digestion on the food matrix, and how processing
conditions (including thermal treatment) may affect susceptibility to simulated gastrointestinal
proteolysis (e.g. Minekus et al., 2014, Smith et al., 2015). However, given the diversity of food
matrices and food processing procedures, our knowledge of their effects on susceptibility of proteins to
digestion is limited. As a consequence, the effects of processing and of the food matrix on the
susceptibility of a particular protein to digestion are difﬁcult to predict. Because there is no effective
animal model for food allergy, studies are often limited to investigating the impact of the food matrix
on elicitation of allergic reactions in allergic human subjects while data on allergic sensitisation is very
limited regarding this aspect (Ballmer-Weber et al., 2002; Bartnikas et al., 2012; Brenna et al., 2000;
Grimshaw et al., 2003; Mackie et al., 2012; Netting et al., 2013; Worm et al., 2009).
Annex B-2. Types of in vitro digestibility tests
The pepsin resistance test, which is embedded in EFSA Guidance Document (EFSA GMO Panel,
2011) and Codex Alimentarius (2003, 2009), is currently used for allergenicity risk assessment as an
additional piece of information within the weight-of-evidence approach, because no single test is fully
predictive of the allergenic potential of a protein. The classical pepsin resistance test has several
limitations (EFSA GMO Panel, 2010) including:
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• the pH value usually employed in the assay is extremely acidic. Because pepsin activity is pH
dependent, the pattern of proteolysis may not reﬂect the one likely to be found in vivo other
than at the end of gastric emptying or in the fasted state;
• pepsin is added in a gross excess to the protein substrate, affecting the kinetics of the
digestion;
• the correlation with allergenicity of proteins has been questioned. Studies comparing the
digestibility of allergens with that of non-allergenic dietary proteins showed that food allergens
were not always inherently more stable to pepsin digestion than non-allergenic proteins (Fu
et al., 2002; Thomas et al., 2004; Herman et al., 2007).
While this test may contribute to understanding the biochemical properties of newly expressed
proteins (information on the physicochemical stability of a protein, such as the rigidity of the
polypeptide backbone at low pH, determine susceptibility to pepsinolysis), it does not allow to
characterise how these proteins behave under the overall physiological conditions encountered in the
digestive tract. Furthermore, the test does not reﬂect changes in the digestive process that take place
across the life course (Remond et al., 2015). These limitations were previously highlighted by EFSA
(EFSA GMO Panel, 2010). In addition, the EFSA Guidance Document for risk assessment of food and
feed from genetically modiﬁed plants (EFSA GMO Panel, 2011) indicates that ‘the digestibility of the
newly expressed proteins in speciﬁc segments of the population such as infants and individuals with
impaired digestive functions may be assessed employing in vitro digestibility tests using different
conditions’. Given these considerations, it is proposed to embed the classical pepsin resistance test
within a suite of tests aimed to characterise how a newly expressed protein may behave during the
digestive process (see Annex B-5).
Gastrointestinal digestion assays usually aim to simulate ‘normal’ digestive function with regard to
digestive enzymes and acid secretion (Macierzanka et al., 2009; Moreno, 2007; Minekus 2014).
However, alterations in the digestive milieu are often observed in patients with various gastrointestinal
conditions (Kay and Jorgensen, 1994), in young infants with underdeveloped digestive system
(Armand et al., 1996) and the elderly with a weakened digestive function (Hosking et al., 1975). In an
in vitro study assessing the impact of digestion on celery allergenicity in an aged population, decreased
gastric proteolysis was identiﬁed (Untersmayr et al., 2008). Simulated infant digestion models (Dupont
et al., 2010; Menard et al., 2014) were used to study the gastrointestinal tolerance of casein and a-
lactalbumin and to optimise the milk processing and formula production. Experiments using simulated
gastric ﬂuid where the pH was increased were used to assess the stability of allergens in ﬁsh, milk and
hazelnut in patients taking antacids where intragastric pH is increased (Scholl et al., 2005; Untersmayr
et al., 2005; Untersmayr et al., 2007). Another study developed a gastrointestinal model simulating the
physicochemical conditions of the elderly’s gastrointestinal tract which was applied to investigate the
fate of bovine whey proteins (Levi and Lesmes, 2014). Finally, the COST Infogest network has
proposed a standardised batch gastrointestinal digestion method based on physiologically relevant
conditions that could be applied for various endpoints (Minekus et al., 2014).
In vitro models simulating the physiological conditions of gastrointestinal digestion (in either healthy
or diseased individuals) by sequential addition of digestive enzymes, biosurfactants and ﬂuids have
been designed to understand the degradation of proteins and other constituents during digestion.
Some in vitro models have also included biosurfactants, such as phosphatidylcholine, which can be
found at low levels in gastric juice and which is also a component of bile (Moreno et al., 2005a;
Mandalari et al., 2009a). Biosurfactants can have complex effects on the phase behaviour of lipid rich
foods, because emulsiﬁcation is an important aspect of lipid digestion (Macierzanka et al., 2009), but
they may also have effects on digestion of proteins associated with lipids, and there is some evidence,
although equivocal, that bile salts may affect the activity of pancreatic proteases. For instance, the
activity of trypsin and chymotrypsin is increased in the presence of bile salts (Robic et al., 2011).
The time course of simulated digestion tests can be based on the residence time of food in the
stomach. This is dependent on the type of meal ingested. For example, liquid and solid meals display
different gastric emptying rates after ingestion (Remond et al., 2015). The half-time (t1/2), which
indicates when 50% of an ingested meal is emptied, ranges from 10 to 60 min for liquid meals,
whereas t1/2 values reported for solid foods ranges from 50 to 115 min. Other factors, such as other
meal components, meal volume, caloric content, ratio between liquid and solid in the meal or the type
of dietary ﬁbres also have an inﬂuence on the gastric emptying rate.
Digestibility studies using gastrointestinal conditions can provide useful data regarding persistency
of newly expressed proteins and/or of digestion derived immunologically active fragments in the
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gastrointestinal lumen which may pose a risk of causing an immune-mediated adverse reaction in a
susceptible individual. The presence of digestion resistant fragments only provides an indication of
exposure of the gastrointestinal mucosal surface and is not on its own predictive of allergenicity,
because this property is a function of the way in which the fragments interact with the individual.
Consequently, resistance to gastrointestinal digestion of a newly expressed protein should be
considered as part of the assessment for its potential to cause allergic reactions via the oral route.
However, it should also be noted that other non-oral routes of exposure such as respiratory or
cutaneous have to be considered (EFSA GMO Panel, 2010).
There is no internationally accepted model/protocol available to perform gastrointestinal in vitro
digestibility tests for puriﬁed proteins although this has been developed for whole foods (Minekus,
2014). This is a consensus model applied to several foods and based on available in vivo physiological
data resulting from the COST Infogest network. This batch in vitro digestion assay includes an oral
phase, as well as subsequent gastric and intestinal phases. Interlaboratory trials were performed at
the European level to assess digestion of skim milk powder (Egger et al., 2016). Such in vitro
digestibility methods will require adaptation to make them useful for analysis of puriﬁed proteins,
taking into account the need for further standardisation and validation.
There are only two validated (ring-trialled) studies of digestibility tests for puriﬁed proteins which
were published up to date:
• Thomas et al. (2004). Modiﬁcation of the seminal paper of Astwood et al., (1996) by lowering
the pepsin:protein ratio and looking at the effect of very acidic pH values (1.2 and 2.0). In
vitro pepsinolysis of 10 proteins (allergens and non-allergens) at pH 1.2 and 2.0 were
evaluated by nine laboratories. The authors observed that pH did not have an inﬂuence on the
time of digestion of protein large-fragments but the detection by gel electrophoresis of low
molecular weight proteolytic fragments was less consistent because the different ﬁxation and
staining methods used;
• Mandalari et al. (2009b). These authors evaluated the in vitro gastrointestinal digestibility of
b-casein and b-lactoglobulin by using a low-protease assay with and without the addition of
phospholipids (based on Moreno et al., 2005a,b and Mandalari et al., 2009a) and the high-
protease assay (based on Astwood et al., 1996 and Fu et al., 2002). Twelve laboratories tested
the method without the addition of phospholipids and ﬁve labs studied the effect of the
addition of surfactants. This study demonstrated that the low-protease assay was robust and
reproducible although further validation should be undertaken using a more extensive panel of
proteins. In addition, this interlaboratory trial showed that the largest factor governing
irreproducibility was the sampling and electrophoresis methods used to analyse digestion
products.
Annex B-3. In vivo pH range and ﬂuids compositions determined in the
gastrointestinal tract
B-3.1. pH conditions in the gastrointestinal tract
There is an increasing body of data on the in vivo ﬂuctuations in pH along the gastrointestinal tract
coming from telemetry studies using single use capsules which house pH and temperature sensors and
a wireless transceiver capable of reporting pH measurements and temperature values with high
precision. Nevertheless, much of the data on infants comes from intubation studies where there are
concerns that the placement of probes in the stomach, may have resulted in an underestimation of
intragastric pH and an over-estimation of the buffering effect of food in pre-term infants (Omari and
Davidson, 2003). Since the presence of food affects luminal conditions, both by virtue of its own
buffering capacity and the stimulatory effect food has on gastric and pancreatic secretions, conditions
are summarised below for both the fasted and the fed state.
B-3.1.1. Stomach
Fasted state: Telemetry studies have shown wide ﬂuctuations in intragastric pH in adults, ranging
from pH 1 to 8 with median values of 1.4–4.6 and an overall mean pH of 2.7 (0.8) (n = 20) (Koziolek
et al., 2015). Other studies also showed fasting intragastric pH to be ~ 2.0 in a group of 12 subjects
(Banerjee et al., 2010), or ranges of 1.5–3 with seven subjects (Ono et al., 2009) and 1.0–2.5 (n = 66)
(Evans et al., 1988). These study groups were dominated by male subjects so no ﬁndings were
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available to show any gender variations. Concerning infants, a recent meta-analysis of data from both
pre- and full-term infants indicated the mean intragastric pH in the fasted infant was 2.8 (0.9)
(n = 102) (Kamstrup et al., 2017).
Fed state: After consuming a meal, the intragastric pH increases due to the buffering capacity of
the food. Thus, intragastric pH in adults is generally around 5.5 and slowly drops to around 1.5 at the
end of gastric emptying (Michalek et al., 2011). In one group of healthy full-term newborns (n = 25),
the pH increased to ~ 6.4 after feeding and gradually decreased to ~pH 3.5 (Mason, 1962). A second
group of 15 healthy preterm infants found that the intragastric pH rose to around 7 after feeding
dropping to 1.5–2.0 at the end of gastric emptying (Omari and Davidson, 2003). A meta-analysis of a
number of studies on the changes in intragastric pH of pre- and full-term infants shows the same
patterns as adults with a higher pH (~ 6.5) immediately after feeding, which reduces over time to
between pH 2.0–4.5 depending on the study (Bourlieu et al., 2014). A second meta-analysis of data
collected in infants (pre- and full-term) showed that the mean intragastric pH in the fed infant is 6.4
(0.6) (n = 102) (Kamstrup et al., 2017).
Drug interventions with proton pump inhibitors (PPI), such as omeprazole or lansoprazole, are used
to treat peptic ulcers and gastroesophageal reﬂux disease in adults and infants (Omari et al., 2007).
Their use results in an increase in fasting gastric pH to 6.0 although the length of treatment required
depends on the dose and form in which the drugs are given (Ono et al., 2009; Banerjee et al., 2010).
Similar effects are observed in infants (Faure et al., 2001). The fed-state intragastric pH of individuals
taking PPIs remains around 6.0 and does reduce but only to around 4.5 at the end of gastric emptying
(n = 10 and n = 7) (Ono et al., 2009; Banerjee et al., 2010).
B-3.1.2. Small intestine
An early study showed duodenal pH to range from 5.0 to 7.2 with a median value of 6.4 which rose
to 7.3 in the distal small intestine (n = 39) (Fallingborg et al., 1989). In a more recent study, fasted
measurements of pH in the proximal segment of the small bowel gave values of 5.9–6.3 with a mean
value of 6.0 ( 0.2) while in the distal intestine the pH was higher at around 7.4–7.8 with a mean
value of 7.7 ( 0.15) (n = 20) (Koziolek et al., 2015). In another study, duodenal pH in the fed state
was found to be 5.2–6.1 (mean of 5.6, n = 17) and did not seem to alter greatly in either the fasted
state or in patients with dyspepsia (Bratten and Jones, 2009). The pH in the distal ileum has also been
found to be ~ 8.1 in both the fed and fasted state. In another study, the mean pH in the proximal
small intestine measured in 55 normal subjects was 6.63 ( 0.53), whereas in the terminal ileum was
7.49 (0.46) (n = 58) (Evans et al., 1988).
There is very little data available on the pH of the intestine in infants (either pre- or full-term) with
only two studies reported. These data indicate that the intestinal pH of infants is 6.6–7.0 and only
drops slightly to about 6.4 after feeding (Kamstrup et al., 2017).
B.3.2. Composition and concentration of digestive enzymes in gastric and
intestinal ﬂuids
The current state-of-the-art reveals that gastrointestinal digestion of proteins is a multistage
process, starting with pepsin cleavage in stomach and proceeding through to the small intestine with
digestion taking place through the action of a mixture of pancreatic endoproteases (such as trypsin,
chymotrypsin and elastase) together with amino- and carboxy-peptidases. Finally, at the intestinal
epithelial surface further digestion takes place through the action of brush border aminopeptidases
(Akimov and Bezuglov, 2012). Collectively, these enzymes reduce proteins down to free amino acids
and the simple di- and tripeptides which can be taken up by transporters on epithelial cell surfaces.
Data on the composition of gastric and intestinal ﬂuids are generally obtained from analysis of
aspirates taken through invasive intubation procedures and consequently data from healthy individuals
are sparse. Furthermore, analysis of ﬂuid composition has generally been undertaken to identify
disease biomarkers. Thus, in contrast to gastric and intestinal pH which is directly measured, the levels
of digestive enzymes are normally reported either in activity levels (directly measured in the
gastrointestinal chyme but using different and non-standardised activity assays, as well as different
deﬁnitions of enzyme units), or in enzyme outputs (ﬂow rates). Interpretation of such data, which is
obtained from ﬂuids generally collected from individuals either in the fasted state or after treatment to
stimulate pancreatic secretion, is further complicated by the fact the caloric content, nutrient
composition, and physical properties of the ingested meal are all known to be factors that can strongly
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inﬂuences pancreatic enzyme secretory responses (Keller and Layer, 2005). Therefore, the comparison
of data from different studies is challenging and makes it difﬁcult to identify well-deﬁned levels and
activities of digestive enzymes to be included in in vitro test systems.
B.3.2.1. Gastric juice
Median values for the pepsin content of gastric aspirates in a study of 20 fasted healthy individuals
ranged from 0.11 to 0.22 mg/mL depending on sampling time (Kalantzi et al., 2006). After eating, the
levels increased from 0.26 to 0.58 mg/mL (Kalantzi et al., 2006). In another study, pepsin activity was
determined using haemoglobin as a standard and found to be 349.1 (14.5) lg/mL using porcine
pepsin A (2,100 U/mg) as a standard (n =343) (Metheny et al., 1997). One drawback of the later
study is that the patient population was heterogeneous (aged 15–95 years; approximately 54% were
> 60 years of age). Around 50% were receiving H2-receptor antagonists and eight omeprazole, a PPI.
Post-prandial measurement indicated that there was 87 U/mL pepsin in preterm infants (n = 28)
(Armand et al., 1996) as compared to levels of 942–1,333 U/mL in adults (n = 6), levels depending on
diet (Armand et al., 1995). In both the Armand and Metheny studies, pepsin activity was measured in
gastric aspirates and using haemoglobin as a substrate. The much lower levels of pepsin, coupled with
higher intragastric pH mean that gastric digestion in infants is very limited (Bourlieu et al., 2014).
The other major gastric enzyme is human gastric lipase. Levels of both gastric lipase and pepsin
increase in infancy as the gastrointestinal tract matures, reaching those of adults by the age of
12 months (Bourlieu et al., 2014). In some instances, gastric ﬂuid can contain bile and often contains
salivary proteins and salivary mucins. The gastric mucus layer contains of surfactant, believed to
enhance its barrier properties with the dominant lipid being phosphatidyl choline and phosphatidyl
ethanolamine (Schmitz and Renooij, 1990). As a consequence, phospholipids ﬁnd their way into the
lumen, with contents of dipalmitoyl phosphatidyl choline ranging between 49 and 95 lg/mL in a group
of 68 children (Chang et al., 2006). In another study, the concentration levels of total phospholipids
found in the gastric juice of healthy adults ranged from 60.8 to 206.4 lg/mL (n = 15) (Wenner et al.,
2000).
B.3.2.2. Pancreatic juice
Pancreatic secretions are highly complex mixtures of proteins, including a wide range of
endoproteases and carboxy- and aminopeptidases, as recent proteomic proﬁling experiments have
demonstrated. For example, proteomic proﬁling of gastroduodenal ﬂuid collected during endoscopy
allowed 71–89 proteins to be identiﬁed in six subjects demonstrated the presence of trypsin,
enteropeptidase, chymotrypsin and elastase although many of the isoforms were not identiﬁed (Paulo
et al., 2010). The gastrointestinal ﬂuid also showed the presence of salivary proteins, such as the basic
proline-rich salivary protein, together with a variety of mucins.
Analysis of pancreatic juice from healthy individuals sampled during endoscopic retrograde
cholangiopancreatography has been undertaken in a limited number of individuals. One study in three
female subjects identiﬁed 90 proteins with a high degree of conﬁdence using MS–MS analysis (Doyle
et al., 2012). Digestive enzymes identiﬁed that degrade proteins include carboxypeptidase A1 and A2,
chymotrypsin C and chymotrypsinogen B1, elastase 2A, 3A, 3B, trypsin 1, peptide prolyl isomerase,
together with other digestive enzymes such as a-amylase 1A, 2A, 2B, carboxyl ester lipase, lipase and
co-lipase and phospholipase A2. The same proteins were identiﬁed in another proteomic proﬁling study
of pancreatic juice from individuals with chronic pancreatitis (n = 9) and a similar number of control
subjects, with the addition of aminopeptidase N and a Xaa-Pro dipeptidase. Semiquantitative analysis
of the protein proﬁles showed that digestive enzymes were downregulated two- to -threefold in
patients with pancreatitis (Paulo et al., 2012).
It has classically been deﬁned that trypsin and chymotrypsin are the most abundant human
pancreatic digestive enzymes making up about 19% and 9%, respectively, of total pancreatic juice
protein (Whitcomb and Lowe, 2007). One of the ﬁrst studies showed the levels of trypsin and
chymotrypsin drop along the length of the intestine (Borgstrom et al., 1957), presumably as a
consequence of their being inactivated or digested. Determination of trypsin in intestinal ﬂuid has
shown there to be 577 ( 44) mg/L immunoreactive trypsin (n = 8) with an enzymatic activity of
11.13 ( 0.12) kU/L of activity (as measured using hydrolysis of N-benzoyl-L-arginine ethyl ester
(Rinderknecht et al., 1978a). A mean post-prandial trypsin activity of 150 U/mL of duodenal juice was
determined in 6 healthy adults (DiMagno et al., 1977). In another study, trypsin was determined in
aspirates using N-benzoyl-L-arginine-p-nitroanilide as a substrate and was determined to be 143
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( 6.7) lg/mL (n = 399) using bovine pancreatic trypsin as a standard (11,000 U/mg) (Metheny et al.,
1997).
Analysis of enzyme activities in pancreatic juice of normal subjects found levels of trypsin of
24.4 mg/g (with a range of 7.7–60.5, n = 20) while chymotrypsin was found at 4.8 mg/g protein
(range of 1–19.4, n = 27) (Rinderknecht et al., 1978a). These authors titrated the enzymes against
bovine standards using N-carbobenzoxy-diglycyl-L-arginyl-2-naphthylamide hydrochloride (GANA) for
the trypsin activity and c-glutamyl-p-nitroanilide (GGPNA) for chymotrypsin although it appeared the
human enzyme was four times less active with this substrate compared to the bovine enzyme when
another substrate was used (Rinderknecht et al., 1978b). Yet another study measured chymotrypsin
activity in duodenal aspirates of healthy individuals and found on average 120.5 international units/ml
of chymotrypsin but no clear indication is given as to the substrate used (Gaia et al., 1984). There is
also data on the analysis of pancreatic tissue from human fetal, newborn and adult origin which
suggest that adult pancreas contains 100 mU/mg protein trypsin while chymotrypsin was around
6 mU/mg protein; however, the methods and reporting units are not clearly described and enzymatic
assays may lack speciﬁcity (Track et al., 1975). Analysis of intestinal contents in a fed state suggested
that trypsin and chymotrypsin levels vary greatly between 50 and 850 lg/mL (Track et al., 1975).
While enzyme activities were measured no indication is given as to how the mass of enzyme in the
intestinal contents was calculated in this study.
Phosphatidylcholine is the main phospholipid found in the lumen of the proximal small intestine,
with an estimated concentration of 3 mM (Carey and Hernell, 1992). In another study, the total
phospholipid concentration determined in the proximal jejunum of healthy adults (n = 6) varied
between 0.1 and 3.9 mM, which resulted from the mixture of endogenous secreted phospholipids and
phospholipids contained in the dietary meal given to the volunteers (Persson et al., 2006). As
previously described, phospholipids have also been shown to affect the rate of protein digestion in the
gastric and small intestinal environments (Macierzanka et al., 2009).
B.3.3. Concentration of bile salts in gastric and intestinal ﬂuids
Conjugated bile salts affect the digestion of proteins by pancreatic proteases such as trypsin and
chymotrypsin, having an effect at concentrations as low as 2 mM, a level below the critical micelle
concentration, although it was more pronounced at 3.5 mM. Thus, bile salts should be included in
model intestinal ﬂuid. While low concentrations of bile salts (0.2  0.5 mM) can be found in the
human fasting gastric ﬂuid (16 out of 36 individuals; Lindahl et al., 1997), concentrations of bile salts
in the intestinal lumen are variable but usually high, estimated in the medium millimolar range
(Martınez-Augustin and Sanchez de Medina, 2008). In agreement with this, the typical concentration of
bile salts found in healthy adults in the fed state is 10 mM in total ﬂuid (n = 20) (Kalantzi et al., 2006);
in another study, the overall bile salt concentration found in the proximal jejunum of healthy adults
(n = 6) in response to a dietary meal varied between 0.5 and 8.6 mM depending on the sampling time
(Persson et al., 2006). The mean bile salt concentration for the fasted and fed state determined in pre-
and full-term infants (n = 214) was calculated to be 4.7  1.4 mM and 1.0  0.3 mM, respectively
(Kampstrum et al., 2017).
Annex B-4. Principles of in vitro protein digestibility tests for risk
assessment
B.4.1. Test conditions
B.4.1.1. Material for testing
With regard to the test protein to be used for the revised/reﬁned in vitro digestibility assays, it is
considered important that the test protein comes from the parts of the plant commonly considered as
edible, at present mostly the seeds/grain, because this material will be consumed.
Therefore, testing of the newly expressed proteins puriﬁed from the edible raw plant material is a
more realistic scenario, if sufﬁcient quality and quantity of the protein is available.
Should strong evidence be provided that the protein cannot be puriﬁed from GM plant material, the
use of recombinant protein may be justiﬁed. Such recombinant protein should be produced in a
manner which allows it to display the same structural, biochemical and functional properties, e.g. post-
translational modiﬁcations (glycosylation, phosphorylation, hydroxylation, carboxylation, disulﬁde bond
formation) as the protein expressed in a plant tissue. An expression system closely matching the
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natural host should increase the structural, biochemical and functional equivalence of the recombinant
protein to the newly expressed plant protein (Hoffman-Sommergruber et al., 2008).
B.4.1.2. Digestion conditions
Digestion conditions should be selected based on the range of conditions found in vivo and which
encompass the needs of special groups and those receiving medication, such as antacids. The current
document provides a set of conditions to reﬂect the different situations experienced in vivo (Annex B-3).
Different concentrations for proteolytic enzymes and/or biosurfactants have also been described in
in vitro digestion models (Dupont et al., 2010; Mandalari et al., 2009b; Minekus et al., 2014, Thomas
et al., 2004) and summarised in Annexes B-3.2 and B-3.3.
An elaboration of the current classical pepsin resistance test would build on both in vivo data and
current in vitro test methodology thus maintaining a link to previous test results and building on best
practice. Different test conditions combining low and high pepsin concentrations with low and high pH
values could potentially be used to represent the range of conditions found in vivo (Figure B.1). For
simulated gastric digestion, one set of conditions that should be considered for inclusion is the current
pepsin test, which represents the low pH conditions observed in the fasted state or at the end of
gastric emptying with an excess of pepsin. Alternative gastric digestion conditions could be included
representing the fed state, and could be followed by an intestinal in vitro digestion step should
digestion resistant fragments be observed.
B.4.2. Data interpretation
Criteria such as length, persistence and abundance of peptides derived from in vitro gastrointestinal
digestion of newly expressed proteins will play a key role in identifying potential hazards within the
weight-of-evidence approach for the allergenicity assessment. The kinetic parameter of ‘half-life’ could
provide means of deﬁning ‘transient’ and ‘persistent’ peptides generated by a given set of digestion
conditions. This has been used in other assessments of the allergenic risk of novel proteins, such as
the ice structuring protein (Baderschneider et al., 2002). However, further evidence to support the
application of such a parameter needs to be obtained. Figure B.2 displays different example scenarios
and possible subsequent data interpretation:
• if a protein digest is composed of peptides < 9 amino acid residues in length, the allergenic
potential can be considered to be low;
• if a protein digest is composed of peptides ≥ 9 amino acids residues in length but transient,
the allergenic potential can be assumed to be low;
• if digestion fragments of ≥ 9 amino acids or longer are identiﬁed and are persistent, further
consideration is required. In such a case, the abundance of the stable peptides ≥ 9 amino
acids in length within the whole mixture of digestion products should be considered in the risk
assessment process. If the abundance of the stable peptides ≥ 9 amino acids in length is
considered to be signiﬁcant, further assessment may be requested on a case-by-case basis.
This may include information on the potential of such digestion resistant fragments to interact
with the immune system. Although additional tests including in vitro cell based assays or
in vivo tests on animal models have not been validated so far for regulatory purposes, they
may be considered useful to provide additional information (EFSA GMO Panel, 2010, 2011). For
non-IgE-mediated allergic reactions (celiac disease), speciﬁc HLA-DQ-peptide modelling and
binding assays, as well as T-cell testing are proposed in this document (see section 2.1
describing Non-IgE-mediated adverse immune reactions to foods). For IgE-mediated allergic
reactions, IgE reactivity and formation of immune complexes may depend on the proximity and
number of IgE epitopes (Huby et al., 2000; Gieras et al., 2016). Therefore, in contrast to T-cell
epitopes, the minimum size of peptides which might act as B-cell receptor epitopes and cause
IgE cross-linking is less clear, and will require the presence of multiple epitopes (at least two)
which can only be accommodated in peptides greater than 9 amino acids in length (Harwood
et al., 2010; Handlogten et al., 2013).
Finally, an appropriate exposure assessment, on a case-by-case basis, is envisaged to allow a more
reliable and accurate allergenicity assessment.
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Annex B-5. Interim phase for reﬁning the conditions of in vitro digestion
tests
General considerations:
During the interim phase, two aspects of the in vitro digestion test should be considered:
1) Test conditions, the interplay between pH, enzyme concentration and duration of the
digestion are key aspects to be considered taking into account data on in vivo conditions.
2) End-points of digestion and objective measurements of the extent of digestion should be
developed which can enable better comparison of test results. This includes (at least)
semiquantitative assessment of the abundance of peptide fragments in a digest and a
deﬁnition of transient and persistent digestion fragments, using concepts such as half-life.
The identiﬁcation of persistent peptide fragments which are ≥ 9 amino acids in length is
critical, because these may indicate that further assessment is required.
Speciﬁc and key considerations:
A) Digestion model conditions: Because the physiological process of digestion is inherently dynamic,
in vitro batch models of digestion inevitably restrict the range of conditions that exist in vivo. To better
reﬂect the range of conditions found in vivo, without overly increasing the complexity of the test, it is
proposed that a minimum of two gastrointestinal test conditions should be used to reﬂect the range
found in vivo. The classical pepsin resistance test should form one part of this testing scenario, having
the added value of enabling comparison with past data collected on resistance of newly expressed
proteins to digestion. (a) pH conditions: The pH employed in the in vitro digestibility tests range from
1.2 to 4.2 with many using pH conditions of 1.2 or 2.0, the former based on the simulated gastric ﬂuid
conditions detailed in the US Pharmacopeia (1995) and used for drug dissolution tests. However,
intragastric pH conditions found in vivo tend only to go down to around pH 2 towards the end of
gastric emptying, and are generally much higher because of the buffering capacity of many foods
(Kalantzi et al., 2006) (Annex B-3.1). (b) Pepsin:protein ratio: Many reports only describe it on a (w:w)
basis and do not take differences in enzyme activity into account. However, the two available ring-
trialled studies of digestibility tests for puriﬁed proteins used a ratio of 10 U (Thomas et al., 2004) and
0.165 U (Mandalari et al., 2009b) of pepsin per lg of tested protein, respectively. (c) Durations of
digestion: Different durations of digestion based on digestion of whole foods have been proposed
(Minekus et al., 2014). Test material is typically exposed to gastric digestion for 60 min followed by
intestinal digestion for 30–60 min with corresponding intermediate sampling time points (Mandalari
et al., 2009b; Dupont et al., 2010). Adaptation and integration of these approaches may provide the
conditions for a reﬁned in vitro digestion test. These adaptations should take in vivo physiological
conditions, described in Annex B-3, into account.
Although a ﬂexible framework for performing the digestion tests is considered in line with the
current considerations, the following recommendations should ensure consistency between the
different laboratories undertaking the tests:
i) The source, purity and speciﬁc activities of digestive enzymes (e.g. pepsin and intestinal
endoproteases) should be determined using standardised protocols. Individual intestinal
enzymes (i.e. trypsin and chymotrypsin) should be prioritised over the use of pancreatin. The
use of individual duodenal enzymes instead of pancreatin should provide a more consistent,
accurate and detailed analysis of protein hydrolysis. In the case of using pancreatin, proteolytic,
lipolytic and amylolytic activity of the extract should be determined and the amount of
pancreatin added should be based on the trypsin activity. Finally and under speciﬁc
circumstances, the use of other intestinal lumen proteases such as elastase and
carboxypeptidases and additional brush border enzymes as aminopeptidases could also be
considered. Further considerations in such respect should take place with the laboratory(ies)
involved in the interim phase.
ii) Enzyme concentrations and activity used in digestion tests should be speciﬁed and could be
based on approaches previously used in interlaboratory studies performed with puriﬁed
proteins (Thomas et al., 2004; Mandalari et al., 2009b) taking into consideration data on
physiological levels reported in human studies (Annex B-3).
iii) Different gastric pH values should be speciﬁed which reﬂect those found in vivo and
encompass those found in infants, adults, elderly or people with impaired digestive functions.
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iv) The addition of biosurfactants (bile salts and phospholipids) at physiologically relevant levels
should be considered. The use of individual and well-deﬁned lipids and bile salt standards
instead of extracts could provide more reproducible and standardised conditions unless the
high quality of the extracts can be guaranteed and assured the non-variability of their
composition among different lots.
It is proposed that, at a minimum, two gastrointestinal digestion test conditions should be
considered. These conditions should encompass the most extensive (such as the current classical
pepsin resistance test conditions) and the less extensive digestion conditions, reﬂective of those found
in fed state in adults and children.
1) Low pH/high [pepsin], these conditions should include those used in the classical pepsin
resistance test (Thomas et al., 2004). In the case that persistent peptides ≥ 9 amino acids
residues in length are detected at the end of the digestion phase, a subsequent intestinal
digestion should be performed (Figure B.1). Based on different physiological conditions
described in Annex B-3, these set of conditions could simulate an adult in fasted state. As
previously mentioned, the interplay between pH, enzyme concentration and duration of the
digestion is a key aspect to be considered, together with the inclusion of gastric
biosurfactants.
2) High pH/low [pepsin] followed by intestinal conditions, if persistent peptides ≥ 9 amino acids
residues in length are detected at the end of the digestion phase. In the gastric phase
physiological conditions reported in in vivo studies and to be considered are the following: a
pH of 5.5 and a pepsin concentration of 1,000 U/mL of gastric juice (when using
haemoglobin as a substrate – see Annex B-3) (Figure B.1). These conditions would reﬂect
those found in the fed state. Again, an important aspect to consider further is the interplay
between pH, enzyme concentration and duration of the digestion, together with the
inclusion of biosurfactants.
In relation to the intestinal phase, a pH of 6.5 could be considered as a physiologically relevant
value which has been reported in the proximal intestinal tract. The evidence available regarding the
concentration and activity of intestinal enzymes observed in vivo is much weaker than for pepsin
concentrations in gastric ﬂuid. For trypsin, it is proposed that a reference value of 145 lg/mL of
duodenal juice, equating to 1,595 U/mL, identiﬁed in vivo (when using N-benzoyl-L-arginine-p-
nitroanilide as a substrate and bovine pancreatic trypsin with 11,000 U/mg as a standard – see Annex
B-3). In relation to chymotrypsin, the data are even more sparse. One approach to deﬁning a level
would be to have a ratio of trypsin:chymotrypsin by mass which relates to the ratio observed in vivo of
2:1 (w/w). In line with previous deliberations, the inclusion of intestinal biosurfactants should be
considered. Finally and given the complexity of pancreatic secretions, the use of other endo- and
exopeptidases should also be considered.
Replication of the in vitro digestion experiments should also be implemented to obtain more reliable
and statistically signiﬁcant results.
B) Control proteins: Digestion studies should be performed including control proteins to
demonstrate the effectiveness of the digestion system employed and allow benchmarking of different
digestion models. The control proteins are not to provide an indication of allergenicity, but rather
reﬂect the different susceptibilities of proteins to gastrointestinal digestion.
For proteins to act as appropriate controls in the in vitro digestion tests, they must be:
1) either commercially available, and/or puriﬁed in reasonable quantities using published
methods and made available for use by the community (e.g. either as quality control (QC)
or reference materials);
2) well characterised with regard to their primary sequence, post-translational modiﬁcations (if
any) and physicochemical state (e.g. size, oligomerisation, pI, hydrophobicity, ligand binding/
prosthetic group);
3) previously subjected to in vitro digestion tests allowing their susceptibility to digestion to be
classiﬁed as either highly resistant, moderately resistant or labile to the action of digestive
enzymes.
One protein which meets these criteria, has been extensively tested in digestion tests and was
found to be extremely resistant to gastric digestion is bovine b-lactoglobulin (Reddy et al., 1988;
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Schmidt et al., 1995; Astwood et al., 1996; Yagami et al., 2000; Fu et al., 2002; Takagi et al., 2003;
Thomas et al., 2004; Sanz et al., 2007; Herman et al., 2007; Lucas et al., 2008; Ofori-Anti et al., 2008;
Macierzanka et al., 2009; Mandalari et al., 2009a,b; Misra et al., 2009; Dupont et al., 2010; Zheng
et al., 2010; Bogh et al., 2013). b-Lactoglobulin has also been reported to be relatively stable under
gastrointestinal digestion conditions (Mandalari et al., 2009a,b; Dupont et al., 2010; Borgh et al.,
2013). On the other hand, phosphofructokinase and/or sucrose synthetase could also be
recommended as control proteins because both enzymes have been described to be rapidly digested
under simulated gastric (Astwood et al., 1996; Fu et al., 2002) and intestinal conditions (Fu et al.,
2002). A representative gluten protein could also be used as control protein.
C) Digestion end-points and read-out considerations: The terms ‘persistent’ and ‘transient’ are used
for classiﬁcation of proteins and peptides with different kinetic behaviour and for fragments in relation
to their rate of formation as well as their rate of further degradation. Kinetic studies are founded on
following the time course of a reaction or process, and hence, there is a necessity for the digestion
tests to take the form of time-course experiments. Consequently, sampling should be undertaken at
various time points during the gastric and intestinal digestion steps, to allow the evolution of peptide
fragments to be monitored. Sampling time points should be selected which are appropriate and will
allow transient and persistent peptides to be distinguished based on kinetic parameters.
Standardised methodology for monitoring protein digestion needs to be used which is suitable for
proﬁling of both large resistant fragments and lower molecular weight peptides of ~ 1,000 Da (the
average mass of a 9 residue peptide fragment). Techniques should also allow at least semiquantitative
proﬁling of residual intact protein and digestion products. Traditionally, protein digestibility has been
measured using SDS-PAGE. However, while providing valuable data especially for intact proteins and
large resistant fragments, this technique is essentially qualitative in nature, can provide inconsistent
results between laboratories and is not an appropriate technique to carry out reliable quantiﬁcation of
peptide fragments. Tandem mass spectrometry, even with caveats with regard to peptide ionisation
efﬁciency, is a more effective tool to carry out a comprehensive peptide mapping of digesta and
identify stable digestion fragments ≥ 9 amino acids in length. Since at present no single methodology
can readily characterise the digestion of both proteins and peptides effectively, a combination of the
best available methodology, such as SDS-PAGE and mass spectrometry, should be used. These
techniques can provide at least a semi-quantitative output of digestion following disappearance of the
intact protein and appearance of digestion resistant fragments.
Replicate analysis should be undertaken using two biological replicates (i.e. digestion tests) being
analysed in duplicate, which is considered the minimum. Best laboratory practice should be addressed
for any methodology such as use of standards, use of appropriate protein stains able to provide a
broad dynamic range and stain many proteins, molecular weight markers (SDS-PAGE) or internal
peptide standards spanning a range of masses (mass spectrometry).
Special attention should be paid to the pretreatment of the digesta before analysis (e.g. analyses
need to take account of maintaining the integrity of disulﬁde bonds during sample handling and
analysis to remain as close as possible to physiological conditions). Hence, the use of reductants or
derivatisation of the sulfhydryl groups of cysteine residues should be avoided if possible. It is
necessary to not only take the presence of covalent linkages (such as disulﬁde bridges) into account,
but also non-covalent interactions, which may lead to smaller peptides assembling to complexes of
higher molecular weight and size.
D) Classiﬁcation of digestion resistant proteins/peptides: A consensus deﬁnition of transient and
persistent proteins and peptides is required that can apply to the different in vitro digestion test
conditions. Control proteins accepted to be highly resistant, moderately resistant and highly digestible
could be used to support development of such a deﬁnition. To do that, an approach based on the
objective measurement of the extent of digestion could be explored. To this end, the half-life of the
intact protein and resulting peptide fragments could be determined and used to establish deﬁnitions of
transient and resistant peptides (Shan et al., 2002; Baderschneider et al., 2002, Herman et al., 2007;
Ofori-Anti et al., 2008; Macierzanka et al., 2009; Defernez et al., 2010; Yao et al., 2013; Smith et al.,
2015).
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Figure B.1: Illustrative examples of in vitro gastrointestinal test conditions and proposed
gastrointestinal conditions for the interim phase
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Figure B.2: Example of possible scenarios resulting from the in vitro digestibility tests and
subsequent data interpretation
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Annex C – Endogenous allergenicity
Annex C-1. History of endogenous allergenicity assessments
Scientiﬁc Opinions on soybean including an assessment of endogenous allergenicity were published
by the EFSA GMO panel (e.g. EFSA, 2007, 2011, 2015, 2016, 2017). Historically, the assessment was
carried out using sera from allergic individuals, e.g. using 2D gel electrophoresis (immunoblot) in
combination with spot quantiﬁcation. More recently, however, novel absolute quantiﬁcation methods
were developed and applicants employed those in the latest applications submitted to EFSA. To date and
considering the EFSA GMO Panel Scientiﬁc Opinions published, no signiﬁcant changes in the allergen
repertoire raising concern was observed in the GM plants assessed. The EFSA GMO Panel concluded that
there was no evidence that the genetic modiﬁcation changed the overall allergenicity of the GM plant
when compared with its conventional counterpart. EFSA is committed to incorporate latest scientiﬁc
developments in its risk assessment process and approaches for endogenous allergenicity evaluation
should be revisited accordingly in the light of the latest novelties in this area.
Annex C-2. Possible approach for selection of soybean allergens to be analysed
The OECD list of ‘potential allergens’ (Table 20 of OECD, 2012) which is based on allergens listed in
the WHO/IUIS database (2011 www.allergen.org) and a review (L’Hocine and Boyne 2007), was taken
as a basis, and further complemented with other allergen databases including the updated WHO/IUIS,
the FARRP allergen database of the University of Nebraska-Lincoln (www.allergenonline.org) and
Allergome (http://allergome.org/). Sequence information was additionally reviewed using the NCBI and
Uniprot databases. Other allergen databases, listed in the EFSA 2010 scientiﬁc opinion (EFSA GMO
Panel, 2010), were also considered, but could not be screened in detail because they did not provide
additional information or were no longer available.
Using these sources, data on individual ‘potential allergens’ and on the allergic individuals tested
were retrieved. Furthermore, information was collected connecting clinical reactivity to total soy
preparations with data on speciﬁc allergens, as well as possible clinical reactions to single puriﬁed
allergens (either isolated from the plant or produced as recombinant allergens). To date, clinical data
for soy allergy were obtained by double-blind placebo-controlled food challenge (DBPCFC) using whole
soybean protein extract or soy ﬂour (Ballmer-Weber et al., 2007), while only limited clinical research
studies, mostly restricted to component resolved diagnostics (Tuano and Davis, 2015), are available for
single proteins. The available information retrieved on the soybean ‘potential allergens’ are listed in
Table C.1 (available in Supporting Information; please see also Selb et al., 2017).
It is challenging to unequivocally connect clinical data obtained on soy extracts by DBPCFC with
reactivity to single proteins. In this particular example, taking the information collected for Table C.1 as
starting point and following the strategy proposed above, deﬁned criteria were applied for a possible
selection of relevant allergens. WHO/IUIS deﬁnes criteria to include a protein in the allergen list. These
are: (i) a minimum of ﬁve sera from allergic individuals (allergic to the allergen source in question)
have to contain IgE which binds to the protein in question, or (ii) at least 5% of the allergic individuals’
sera tested react with the allergen in question by IgE binding. It is noteworthy that WHO/IUIS
database was the main contributor for listing allergens in the OECD document on soybean. WHO/IUIS
is also mentioned as a key reference for listing allergens in the EFSA NDA Panel opinion on food
allergens (See section 8 of EFSA NDA Panel opinion 2014). WHO/IUIS committee meetings deciding
the inclusion of new allergen in the list are held in the frame of EAACI and AAAAI international allergy
meetings. Notably, because an application must be ﬁled to include a protein into the WHO/IUIS
database, not all proteins clearly fulﬁlling the requirements are included in the current database. In our
example approach following the current WHO/IUIS criteria, the following allergens listed in Table C.1
are also part of the WHO/IUIS database and should be measured accordingly: Gly m 1, Gly m 2, Gly m 3,
Gly m 4, Gly m 5, Gly m 6, Gly m 7 and Gly m 8. Out of these, Gly m 2 can currently not be measured
since the sequence is unknown. The following proteins potentially fulﬁl the primary WHO/IUIS criteria
of required tested allergic individuals, but did not undergo an expert peer-review by the WHO/IUIS
committee: Gly m Bd 28 K, Gly m Bd 30 K, soybean lectin, lipoxygenase, Kunitz trypsin inhibitor and
Gly m 50 KD. Out of these proteins, for Gly m Bd 28 K, Gly m Bd 30 K and Kunitz trypsin inhibitor
considerable peer-reviewed literature is available and endogenous allergenicity measurement was
previously suggested by other scientists (Ladics et al., 2014). In this context, international recognition
and/or clinical relevance should be the main aspects to consider for the selection of proteins that will
require an endogenous allergenicity assessment.
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In contrast, the evidence for the involvement of soybean lectin and lipoxygenase in soy allergy is
more scarce (evidence from peer-reviewed scientiﬁc literature is limited/non-existent), and additional
evidence from clinical studies would be useful. Gly m 50KD is currently not measurable since the
sequence is unknown. The other listed proteins, Gly m 39KD, P22-25, Gly m CPI, Gly m EAP and the
‘unknown possible allergen’ currently do not fulﬁl the primary WHO/IUIS criteria. Measurement of
these would therefore not be performed at the current time. However, more evidence might become
available in the future. It should be noted that the above stated considerations (i) might be incomplete
and (ii) do not prevent a revision of the scientiﬁc progresses in science at any time in the future, which
might considerably change the list of potential allergens suitable for assessment as well as the
necessity to rank their relevance for the safety assessment.
Even though food allergy to soybean is known in animals (Suto et al., 2015; Kang et al., 2014),
importantly, limited data are available on relevant individual soybean allergens in animals. However,
certain proteins known to cause soybean allergy in humans (e.g. Gly m 5, Gly m 6) also caused
reactions in calves, piglets, dogs and other animals (Taliercio et la., 2014; Lalles and Peltre, 1996;
Dreau et al., 1994).
Annex C-3. Methodology
For ELISAs, individual allergens should be quantiﬁed using puriﬁed monoclonal or polyclonal
antibodies raised against each puriﬁed allergen molecule. The measurement should be performed
together with calibrated standards to ensure adequate information on allergen quantities in a sample.
Protocols for allergen quantiﬁcation by quantitative ELISA were developed previously (Geng et al.,
2015, 2017; Chen et al., 2014; Hei et al., 2012; Liu et al., 2012, 2013).
Mass spectrometry (MS) approaches can also be used to speciﬁcally detect and quantify single
allergens. MS protocols for the assessment of endogenous allergenicity of soybean were developed for
some potential allergen molecules (Kuppannan et al., 2014; Stevenson et al., 2012; Houston et al.,
2011).
The standardisation and harmonisation of these analytical methods among applicants would be
beneﬁcial to enhance measurement comparability. This would support the future establishment of an
allergen database, including data on the natural variability, which would provide useful additional
information to improve the robustness of the safety assessment.
Annex C-4. Data interpretation and risk assessment considerations
According to IR503/2013, after comparison to a conventional counterpart within the comparative
analysis, natural variability is currently considered the main tool to identify signiﬁcant and potential
relevant changes in allergen content. The European Commission clariﬁed this issue further.9
Currently, the experimental ﬁeld design for comparative compositional analysis requires the
inclusion of at least six non-GM reference commercial varieties – the selection of which should be
justiﬁed according to deﬁned criteria (see section 1.3.2 of IR503/2013). These varieties are used to
estimate the overall natural variability to which consumers are routinely exposed. The application of
such an approach allows an objective comparative evaluation independently of the absolute content of
endogenous allergens ensuring a high degree of protection for consumers.
It is recognised that the natural variability of any given endogenous allergen content estimated
from the reference commercial varieties, even if appropriately selected, may not capture the full range
of its variability, which is currently unknown. Further efforts in such respect would be beneﬁcial, as
described in Annex C-3.
Finally, speciﬁc considerations associated with a particular allergenic risk have to be taken into
account. Among others (see also Selb et al., 2017), the following considerations are of principle
relevance:
• exposure to a certain allergen should be taken into account as a last step in the risk
assessment process with particular interest in understanding levels of allergens in foods
derived from soybean varieties consumed in Europe by humans and animals at a given time;
• efforts to reduce the uncertainty could be deﬁned according to the single allergen in question
for which enhanced allergen content was encountered and for which there is a potential
9 Letter from European Commission to EuropaBio (Ref. SANCO/El/SP/mb sanco.ddg2.e.l(2014)l 140685) where it was clariﬁed
that ‘allergens included in the compositional analysis should be treated as any other compound meaning that allergens in the
reference varieties included in the assessment should also be analysed (so that an equivalence test as well as a different test
can be performed)’.
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increase in allergenicity to be communicated to risk managers. The relevance of any given
increase might be evaluated with the help of clinical scientist, taking into account: (a) the
magnitude of the increase, (b) the potency of the increased potential allergen in question, (c)
the overall percentage of the allergen in the non-GM crop and the consequent possible impact
of an increase, (d) the route how the allergen is encountered by the allergic individual, (e) the
frequency of the potential allergen in question in various products;
• depending on the level of uncertainties identiﬁed and, in the case of need, the allergenicity of
a GM plant can be compared with that of its appropriate comparator by DBPCFC. This would
imply performing a clinical study investigating the reactivity of selected allergic individuals to
the varieties under assessment. Therefore, well-characterised allergic individuals reacting with
the allergen in question would have to be challenged;
• as a future consideration/perspective, the probability of elicitation of an allergic reaction could
be further investigated with the help of dose–distribution curves (Ballmer-Weber et al., 2015)
obtained by DBPCFC to single allergens (Kinaciyan et al., 2016) and with reference values (e.g.
threshold of elicitation) more precisely evaluated.
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